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 ABSTRACT 
STUDY OF ANTI-PROLIFERATIVE ACTIVITY OF INSPIRED ESTRONE 
ANALOGS ON HEPATOCELLULAR CARCINOMA 
SARA ELGAZWI 
2018 
Hepatocellular carcinoma (HCC) is considered the third leading cause of death 
from cancer. Overall survival rate is significantly low, due to the emerging resistance 
to chemotherapeutic agents and lack of selectivity. Recent studies have demonstrated 
that epidermal growth factor receptor (EGFR) is a promising molecular target for 
cancer therapy, especially HCC. Current studies showed that cucurbitacins are potent 
anticancer compounds which target EGFR. This prompted us to investigate the anti-
proliferative activity of novel cucurbitacins inspired estrone analogs (CIEA) against 
sensitive and resistant HepG2 cell lines. Anti-proliferation activity of 20 CIEA analogs 
were examined against HepG2 using MTT assay and showed that antiproliferative 
activity of analogs MMA132, and MMA102 IC50 are 2μM, and 3 μM respectively in 
comparison to Erlotinib 25 μM. Study of the mechanism of anti-proliferation effects of 
these novel analogs was elucidated. Western blot analysis showed that MMA132, and 
MMA102 significantly inhibit EGFR/pEGFR, RAF/pRAF, MEK/pMEK, and 
ERK/PERK. Cell cycle analysis on HepG2 cell line revealed that MMA132 and 
MMA102 arrested the cells at G1 phase and inhibited the HepG2 cell migration after 
24 hr. MMA132 induced apoptosis through activation of caspase 3,9 and inhibition of 
PARP.  
Treatment of HepG2-R (Erlotinib resistant) with MMA132 and MMA102 showed 
that these two novel drug candidates still possessing potent anti-proliferation activities 
against HepG2-R. Further characterization of the anti-proliferation of these lead 
compounds was demonstrated through mapping the change in EGFR signaling pathway 
(ERK, pERK, RAS, AKT and MEK) by western blot, cell cycle analysis, demonstrated 
that MMA132 and MMA102 stop the cell cycle of HepG2-R at G2 phase and inhibited 
cell migration after 48hrs. HepG2-R cell line significantly expressed MRP2 in 
comparing to sensitive cells. Moreover, MK571(MRP2 inhibitor) showed an inhibitory 
xiii 
 
 
 
effect on resistant HepG2-R cancer cell lines. Combination of MMA132 with MK571 
(13 µM and 15 µM respectively) showed a significant increase in the cytotoxicity of 
MK571 from 18.5 µM to 10 µM. In conclusion, our study documented the discovery 
of novel estrone analogs as potential drug candidates for treatment of HCC and 
promising chemotherapeutic agent toward HepG2 resistant to erlotinib. 
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 Chapter One 
1. General Introduction and Background 
1.1 Hepatocellular Carcinoma 
          Hepatocellular carcinoma is the sixth most common cancers with about 500,000 
people diagnosed each year, and it’s reported as a third largest cause of cancer –related 
death1,2. The treatment is challenging, 5-years survival rate is estimated to be less than 
5%3.The most common causes of death among HCC patients are recurrence, 
metastasis, and the development of new primary tumors4. 
1.2 Causes for Hepatocellular carcinoma 
  Many risk factors are responsible and play role in HCC progress. Induced 
Hepatitis C, B virus (HCV, HBV) infection are associated with the highest HCC incidence 
in persons with cirrhosis, the data about HCC risk is still limited but factors like older age, 
male sex, the severity of compensated cirrhosis, and sustained activity of liver disease are 
important predictors of HCC. More studies are needed to demonstrated the mechanism of 
factors such as HBV genotype/mutant, occult HBV, HIV confection and other risk factors 
that cause HCC (e.g., obesity, diabetes)5. (Figure 1.1)  
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Figure 1.1 Causes of Hepatocellular carcinoma (HCC). 
 
1.2.1 Virus induced hepatocarcinogenetic 
Approximately 2 billion and 170 million people around the world infected by 
hepatitis B virus (HBV) and hepatitis C virus (HCV). There are many different mechanisms 
to promote HCC by HBV and HCV, by target and binding to growth factors and thus 
promote cellular growth, survival and by pass the DNA-damage checkpoints. HBV is one 
of the Hepadnaviridae families, which is an enveloped DNA virus. It is a very common 
viral disease, about 320,000 people die annually due to complications of HBV infection. 
Asia and Africa reported to  have the highest  HBV incidence worldwide 6.In addition, 
HCV is a member of the Flaviviridae family which is a single-stranded RNA non-
cytoplasmic type virus. It is a contagious virus that can contribute to infection by direct 
blood contact, perinatal from mother to fetus, and in rare cases, by sexual intercourse. 
China, Egypt, and Pakistan have the highest number of HCV cases worldwide7’8. HCV has 
been reported to have biological properties compared to HBV, HCV is an associated 
hepatocarcinogenetic. Because HCV has a better tendency (60-80%) to produce chronic 
infections compared to HBV, which has only a 10% tendency. This tendency is connected 
to HCV's ability to generate a fast rate of replication errors that can cause immune evasion. 
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1.2.2 Alcohol induced hepatocarcinogenetic 
 Alcohol consumption is one of the significant causal factors for HCC. Chronic 
alcohol addiction causes pre-inflammatory cytokines by activating and disturbing the 
monocyte later will lead to an abnormal evaluation circulating endotoxin concentration. 
These bring about hepatocyte damage9. In the case of chronic ethanol toxicity, the 
hepatocyte demonstrates a high sensitivity to the TNFα cytotoxicity effect, which is a clear 
sign of chronic hepatocyte disturbance, activation of the stellate cell, liver cirrhosis, and 
eventually10. However, alcohol can affect and damage the liver via a process called 
oxidative stress. Three mechanisms can be explaining the connection between oxidative 
stress and the liver damage that leads to HCC. First, oxidative stress induces the 
progression of cirrhosis and fibrosis, which are considered the main causes of HCC11. 
Second, oxidative stress that results from ethanol toxicity has a relevant effect on the HCC-
signaling cascade, such as a decrease in the tyrosine phosphorylation of the signaling 
transducer and the activator of transcription I (STATI)12.Third, oxidative stress in some 
cases increases the rate of telomere shortening which may interrupt the DNA replication 
process and cause HCC13. In addition, Alcoholic liver disease (ALD) it’s a factor leads to 
cirrhosis and later HCC because (ALD) cause liver injuries such as steatosis, steatohepatitis 
and consequently HCC. But generally HCC doesn’t develop in absence of cirrhosis, just in 
heavy alcohol intake without cirrhosis it the obvious risk factor in some HCC patients14. 
1.2.3 Obesity and type 2 diabetes 
       Obesity has been found to be a primary risk factor for some cancers including breast 
cancer, endometrial cancer, colon cancer, renal cell carcinoma, esophageal 
adenocarcinoma, and HCC. Extensive studies have confirmed a strong link between 
obesity and HCC (Figure 1.2)15. The obesity and type 2 diabetes are the factors causing 
the development of non-alcoholic fatty liver disease (NAFLD) and progress of HCC. In 
United State the number of NAFLD associated with HCC was reported to increase to 9%. 
Beside the role of obesity in HCC, genetic factors also have an essential role in metabolic 
syndrome of the obese patients and subsequently to HCC. Increasing the free fatty acids 
from triacylglycerol (TG), in obese case will cause the release of tumor necrosis 
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factor (TNF-α) from recruited macrophages and decrease secretion of adiponectin which 
considered as an insulin sensitizer. So, in the end hepatic lipogenesis is increased due to 
induced TG content leading to development of insulin resistance which will cause 
stimulation of the transcription factors (SREBP1, ChREBP1) which play role in promotion 
of hepatocarcinogenetic.  
 
Figure 1.2 Three putative mechanisms for obesity-induced and obesity-promoted 
hepatocarcinogenesis 
 
1.2.4   liver Cirrhosis 
             Liver cirrhosis is consider as the main reason for HCC development, which is 
mainly caused by the most two common liver’s viral infection, HBV and HCV16,17.The 
development of cirrhosis usually occurs  when patients have a chronic liver disease over a 
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period of years, which can be distinguished by a decrease in hepatocyte proliferation as a 
sign of liver damage. This causes an increase in the fibrous tissue and a disturbance of liver 
cells that leads to the development of liver cancer. Table 1.1 shows the annual percentage 
rate of HCC from cirrhosis caused by viruses or liver complications16. 
          While these results show HCC progression by liver cirrhosis caused via different 
liver diseases, the development of HCC may also include additional mechanisms18,16.  Many 
studies have found the exact mechanism associated with HCC development from liver 
cirrhosis, but only a few possible mechanisms have been proposed, including micro- and 
macro-environmental changes that induce cellular proliferation and telomerase 
dysfunction19. 
Table 1.1 Annual Percentages of HCC Incidences Caused by Liver Cirrhosis. 
Underlying disease Annual incidence (%) 
HCV 1-8 
HBV 1-15 
Alcohol liver disease 1 
Nonalcoholic 
steatohepatitis 
2.6 
Hemochromatosis 2-6 
Primary biliary cirrhosis 2 
Autoimmune hepatitis <0.2 
 
1.2.5 Fungi-induced hepatocarcinogenetic 
 Mycotoxins are considered a fungal secondary metabolite with different toxic 
effects. Aflatoxin B1 one of many mycotoxins is a food contaminant produced by the fungi. 
In addition, it is also known as a carcinogen and is involved in p53 mutation and induction 
of HRAS oncogene mutation. AFB1 is activated when it is absorbed in the blood circulation 
and metabolism to AFB1-exo-8, 9-epoxide. The active metabolite binds to DNA and 
damages it, so it can be distinguished by the activation of the P53 protein1. This DNA 
damage has been founded in 30- 60% of HCC patients in AFB1 epidemic regions2.  
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1.3 Diagnosis of HCC: 
            The main challenge in HCC remains the early diagnosis which allows potential 
treatment approaches. Various tests used to diagnose HCC, include imaging, histology and 
serological tests. Imaging tests, such as ultrasound (US), computerized tomography (CT) 
and magnetic resonance imaging (MRI) can be used to detect hepatic nodules20,21. Monitor 
and control of cirrhosis in patients of any etiology may decrease tumor-related mortality 
22. Beside the cirrhosis the value of α-fetoprotein (AFP) and newer biomarkers such as 
lectin-bound AFP (AFP-L3) as surveillance needed to define their significance23. In 
general, gene expression profiles, proteomic and recent progress in metabolomics can act 
as potential biomarkers. This will help in the identification of HCC development and may 
serve for monitoring therapeutic response22. 
1.4 Stages of Hepatocellular carcinoma: 
           Staging of hepatocellular carcinoma is a critical step in management of patients and 
HCC treatment. Because any of these stages should be linking with treatment indication 
and this should be based on strong scientific data24. The Barcelona Clinic Liver Cancer 
staging system is concluded in figure (1.3)25 which is important to  treatment of HCC 
patients based on this staging system26. 
The BCLC recognizes the following five stages of HCC: 
1.4.1  Very early stage (BCLC 0) 
 This stage can start in patients who have single HCC smaller than 2 cm in cirrhotic 
liver without clinically related portal hypertension. Because these small tumors have a very 
low chance of microscope dissemination, especially if they were related to indistinctly 
nodular type27. 
1.4.2  Early stage (BCLC A) 
 In this stage patients have single HCC or nodules up to three or less than 3cm.  The 
function of the liver is defined by Child-Pugh A and Child-Pugh B status not reaching the 
criteria for transplantation25. 
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1.4.3  Intermediate stage (BCLC B) 
 This stage is characterized by those patients with multifocal/large disease who are 
asymptomatic and do not present vascular invasion or extrahepatic spread Liver function25.  
1.4.4  Advanced stage (BCLC C) 
  For this stage is formed by those patients with extrahepatic spread, vascular 
invasion and / or mild cancer-related symptoms. Liver function in this stage is not well 
confirmed as a prognostic predictor, in addition the presence of ascites may a worse 
prognosis28 . 
1.4.5  End stage (BCLC D) 
 This include those patients with severe impairment  of liver function (Child- 
PughC) who are not allowed for liver transplantation and those who they have heavy 
impaired physical condition as established by an ECOG performance status >228. 
 
Figure 1.3 The Barcelona -Clinic Liver Cancer (BCLC)staging system for HCC. 
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1.5 Current treatment of HCC: 
 Treatments for HCC depend on the extent (stage) of the disease as well as the age, 
overall health, the type of local medical resources and personal preferences, there are 
various treatment choices available for HCC26. Treatment of HCC is divided into two 
types; curative and palliative. The curative treatment for HCC treatment include ablation, 
surgical resection and liver transplantation; these usually provide a high percentage of 
treatment response which increases the survival rate. For the second type, the palliative 
options of HCC treatment, such as chemotherapy and radiotherapy, do not tend to provide 
a high rate of response compared to the curative options, but they can improve the survival 
rate of HCC patients in general29. 
1.5.1  Surgical Resection 
            HCC patients with a non-cirrhotic liver, an early stage of HCC and the liver health 
and function are good candidates for the resection surgery. The process of liver resection 
it is done by removing the specific part of the liver that has the tumor mass, along with a 
small range of liver tissues around the mass, leaving the healthy part of the liver to renew 
the whole organ. Among all the HCC treatments choices, surgical resection for the early 
stage of HCC is considered the best choice because it provides complete extirpation of the 
tumor mass and keeps the liver function regeneration30. But, treatment with surgical 
resection has some limitations for curing HCC. First, some clinical tests should be made 
on the liver to ensure that the remaining part of the liver has the ability to renew the liver 
function. For example, HCC patients with liver cirrhosis are not suitable for surgical 
resection. Second, removing the liver tumor mass will not remove the tumor completely, 
that means will increase the chances of generating a de novo primary tumor mass. The 
statistical studies indicate that 75-80% of HCC patients who have had the tumor mass 
removed will survive. Third, if the patient has several tumors the chance of treating HCC 
by surgical resection will be small. In addition, the HCC cases that diagnosed at the late 
stages with the association of liver cirrhosis will make surgical resection an impractical 
option22. 
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1.5.2 Liver Transplantation 
            Liver transplantation is considered one of the best curative treatment options for 
HCC patients with one tumor nodule less than 5 cm or up to three nodules each less than 3 
cm, especially in the early stages22, since it removes the whole liver including its tumor 
masses. It thus provides a solution for the underlying cirrhosis. On the other hand, the main 
problem with liver transplantation is the spread of the tumor to another organ. There are 
criteria Knows as the Milan criteria, which are criteria used to distinguish HCC patients 
who are suitable for liver transplantation. These criteria include: a solitary tumor < 5cm in 
diameter, total of 3 lesions <3cm in diameter, and no spread of the tumor to the other organs 
or vessels. The Milan Criteria increased the survival rate to 80% and returning survival rate 
to 83% after liver transplantation31. 
1.5.3  Local Ablation 
           Local ablation is usually performed in early-stage disease for those who are not 
candidates for resection or transplantation22. Ablation therapy provides local management 
of the HCC cancer cells with only a small influence on the neighboring cells and other 
hepatic tissues. The three types of ablation therapy include radiofrequency ablation (RFA), 
percutaneous ethanol injection (PEI) and microwave ablation (MWA). RFA uses an 
electrical current with a high frequency to deliver heat to the liver tissues and cause 
coagulative necrosis, however, RFA will continue to be the first-line therapy in nonsurgical 
patients with small lesion until more effective technique are established. PEI mainly causes 
liver cell dehydration, which is responsible for the death of the exposed liver tissues, also 
produces coagulative necrosis. Unlike RFA, MWA generates heat by applying an 
electromagnetic source to the liver tissues that can cause the tumor masses to die30.That is 
why chemotherapy is another option for HCC treatment.  
1.5.4 Chemotherapy 
The name chemotherapy is referred to a systemic therapy using small molecule 
drugs to target various signaling pathways. However, treatment of HCC with chemotherapy 
agents has not been very promising to date and suffers from the drawbacks of dose-limiting 
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toxicity, developing of multidrug resistance and unfavorable side-effect such as other 
cancers. since they have not increased the survival rate. The major reason for this is 
multidrug resistance associated with most of the drugs available32. Multiple goals are 
possible when using chemotherapy to treat HCC patients, including curing cancer, slowing 
cancer growth, and treating cancer symptoms33. In general, four anti-cancer drugs types are 
available, including alkylating agents, antineoplastic agents, intercalating agents and 
molecular target anti-cancer agents. However, the Food and Drug Administration has 
approved only a few drugs for the treatment of HCC (Sorafenib and Erlotinib), which are 
considered molecular target anti-cancer agents34.  
1.5.5  Radiotherapy 
           Radiotherapy(RT) is another option for the treatment of HCC. Its application of 
radiotherapy has increased recently decades, and also the studies using the latest 
technologies, such as stereotactic body radiotherapy (SBRT) or proton therapy has 
increased. Many researchers have reported effective clinical outcomes for patients with 
HCC using RT. This therapy can achieve necrosis by killing the tumor cells in a small liver 
tumor mass. However, radiotherapy has some risks for the patients, such as causing 
abdominal injuries or extensive hepatitis. For these reasons, the use of this technique for 
treating HCC is very limited35. 
1.5.6  Treatment Strategies of HCC by Molecular Target 
           Treatment of HCC can be done by either liver transplantation or surgical resection 
if diagnosed in its early -stages. However, majority of the HCC cases are discovered in the 
late stages, which cause poor survival rate 36. The main reason for this decreasing in the 
survival rate is the lack of effective chemotherapeutic agents that can cure HCC in its late 
stages. Many studies have demonstrated that only 10-20% of HCC patients respond to the 
chemotherapy treatments, with toxicity and cellular resistance to available 
chemotherapeutic agents being the main problem to successful treatment 37. Searching for 
new active molecular target anti-cancer agents for HCC has become a popular area for 
research due to the urgent need to overcome the toxicity and cellular resistance problems. 
In addition, molecular targets is essential for the discovery of a therapeutic treatment that 
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overcomes the resistance and decreases the side effects 38. Hepatocellular carcinoma 
(HCC) is a diverse and complex tumor with many variations in genome. Irregular 
activation of several signaling cascade has been shown by previous research. For example 
epidermal growth factor receptor (EFGR), RAS/extracellular signal-regulated kinase, 
phosphoinositol 3-kinase/mammalian target of rapamycin (MTOR), hepatocyte growth 
factor/mesenchymal-epithelial transition factor, Wnt, Hedgehog, and apoptotic signaling39 
. 
1.5.7 Disrupted Signaling Pathways and Targeted Therapies 
             The molecular aberrations described protein kinase as the main targets for liver 
cancer therapy. Description of the whole protein kinases pathway a few years ago has 
helped the discovery of new oncology drug .The key signal transduction pathways involved 
in the pathogenesis of HCC are Wnt-βcatenin pathway, EGFR-RAS-MAPKK pathway, c-
MET pathway, IGF signaling, Akt/mTOR signaling, and VEGF and PDGFR signaling 
cascades Figure (1.4)40. In addition, targeted therapies developed for these pathways are 
summarized in Table(1.2)39. 
 
Figure 1.4 Activation of EGFR leads to downstream signaling pathways that ultimately 
drive tumor proliferation or impair apoptosis. 
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Table 1.2 Molecular Targeted Agents in Clinical Development in Cancer: 
Cancer cell 
function 
Target Agent (type) 
Signal 
transduction 
Growth factor 
receptor 
EGFR 
Gefitinib (TKI), Erlotinib (TKI), 
Cetuximab (mAb), Panitumumab 
(mAb) 
HER 
Trastuzumab (mAb), Lapatinib 
(TKI) 
PDGFR 
Imatinib (TKI), Sunitinb (TKI), 
Sorafenib (TKI) 
FLT3 
Lestaurtinib (TKI), PKC 412 (TKI), 
sunitinib 
Intracellular signaling 
RAS 
Farnesyl transferase inhibitor 
tipifarnib. 
RAF Sorafenib. 
MEK Vandetanib, AZD6244. 
MTOR 
Temsirolimus, everolimus, 
rapamycin. 
Angiogenesis 
Growth factor VEGF Bevacizumab (mAb) 
Growth factor 
receptors 
VEGFR 
(1–3) 
Sorafenib, sunitinib, Britain, 
cediranib, Valatanib, IMC1121B 
(mAb) 
PDGFR Sorafenib, imatinib, sunitinib. 
Apoptosis 
Intrinsic pathway BCL2 GX15-070, oblimersen 
Extrinsic pathway Apo2L/TRAI 
Mapatumumab, Apomab, AMG-
655, rhApo/TRA 
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1.5.8  Growth Factor Receptor Signaling: 
1.5.8.1  EGFR-Ras-MAPKK Pathway 
The EGFR is a member of a family of four related receptors (Her2/Neu, ErbB3, and 
ErbB4) that upon ligand binding trigger tyrosine kinase activity and consequently initiate 
signal transduction. The function of EGFR classically occurs because of point mutations, 
amplification, or increase in ligand-receptor interaction41. Activate of the RAS/MAPK 
signaling pathway and induce transcription of genes of the AP1 family, such as c - fos and 
c - jun , which play an important role for cell proliferation it’s done by the ligands EGF, 
hepatocyte growth factor (HGF), PDGF, and VEGF39.  In addition, effective blockade of 
the EGFR signaling pathway can be achieved using monoclonal antibodies against EGFR 
(cetuximab) or ErbB2/Her2/neu (trastuzumab). In HCC, Ras/MAPK pathway activation 
might cause aberrant upstream signals (EGFR signaling, IGF signaling) or inactivation of 
tumor suppressor genes by aberrant methylation42.  
Therefore, inhibition of the EGFR-TK signaling cascades are promising potential 
approach for the treatment of hepatocellular carcinoma (HCC). In the signaling cascade, 
both upstream or downstream targets of EGFR can be used for the treatment of any cancer 
in general and HCC specifically43’44. Many organic compounds, such Erlotinib, have 
shown potent inhibitory activity against EGFR by inhibiting its phosphorylation; these are 
known chemotherapeutic agents for the treatment of HCC. Erlotinib (Tarceva) is a very 
active and selective inhibitor of the EGRF-TK protein. It has an advantage over most of 
the anti-cancer agents in that it can be taken orally, inhibits cellular proliferation and causes 
cell cycle arrest at the G1 phase. In addition, it has been approved as an active drug for 
pancreatic and lung cancer by the FDA but is still in Phase II clinical trials as an anti-cancer 
drug for HCC45. 
1.5.8.2  Vascular Endothelial Growth Factor (VEGF)  
                HCC is as hypervascular cancer and has a large amount of tumor vascularity. 
VEGF is connected to the angiogenesis of various cancer types and HCC is  one of them 
whose progression is enhanced by VEGF46. HCC and all other tumor masses need blood 
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vessels to survive and enlarge, as a result these blood vessels are considered abnormal since 
they are responsible for the high fluid pressure inside the tumor mass. Therefore, VEGF as 
a targeting agent may cause a decrease in the tumor vessels' supplies and their sinuosity 
and consider to be a promising target therapy, which leads to a decrease in the internal 
pressure of the tumor mass. All of these processes will lead to normal blood vessels 47. In 
2005, Gerber et al confirmed  the ability of anti-VEGF drugs, in combination with other 
anti- cancer agents, to cause a fast decrease in the internal vessel pressure of the tumor 
mass, which resulted into faster targeting of the agents to the tumor mass, a decrees in the 
tumor size and an increase in the survival rate 48. A lot of agents have been designed to 
treat HCC by targeting VEGF or VEGFR. Some of them have been proven effective, such 
as Erlotinib Figure (1.5), and some are still in clinical trials to verify their pharmacokinetic 
profiles. Erlotinib is one of the first molecular target drug approved by the Food and Drug 
Administration (FDA) for the treatment of HCC. It is considered a multi-kinase agent that 
stops tumor cell proliferation by inhibiting different molecular targets, including VEGFR 
and PDGFR tyrosine kinases, which produces an anti-angiogenic effect. In addition, it 
targets the downstream cascades such as the Raf/MEK/ERK signaling pathway49, 50 Figure 
(1.5). 
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Figure 1.5 Structures of known Chemotherapeutics that target EGFR for treatment of 
HCC. 
1.5.8.3  Mitogen Activated Protein Kinase (MAPK) Pathway 
              MAPK includes, in its downstream, four main kinases Ras, Raf, MEK and ERK 
Figure (1-5) which connect to each other by phosphorylation. They play role in cell 
division, growth and regulation. These downstream proteins are connected to the upstream 
receptors such as PDEFR, EGFR, and VEGFR Figure(1.5)51,52. The MAPK pathway is an 
essential player in the growth and survival of HCC cells, which makes it a promising target 
for the treatment of HCC39, 53 . ABT-100 is one of the anti-cancer agents in phase II clinical 
trials that inhibits the farnsylation process of the protein Ras by inhibiting the enzyme 
farnesyl transferase, later leads to a decrease in tumor cell growth51,54 . The family of the 
protein Raf includes three members: A-Raf, B-Raf, C-Raf. Hyperactivation of C-Raf (wild 
type) in various cancer types, including HCC, was the only reported one, which makes it a 
valuable target for treating HCC55. Sorafenib is an approved HCC chemotherapeutic agent 
that inhibits B-Raf, C-Raf, FGFR, PDGFR and VEGFR56. The family of the protein MEK 
includes two subunits, MEK1 and MEK2have been reported that overexpression of MEK1 
and MEK2 lead to an activation of ERK1 and ERK2; in the case of HCC, this could be 
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happening in different percentages. For more, it has been proven in vitro studies that the 
addition of a MEK1 or MEK2 inhibitor to HepG2 or Hep3B HCC cell lines will inhibit the 
autophosphorylation and cause cell apoptosis. MEK inhibitors, including include 
Selunetinib, RDEA119 and ASCO2010, are still in phase II clinical trials57. 
1.5.8.4  PI3K/Akt/mTOR Pathway 
              The PI3K/Akt/mTOR pathway has a critical role in carcinogenesis58. Akt can be 
activated through tyrosine kinase receptor (EGF or IGF signaling) or through organized 
activation of PI3K or loss of function of the tumor suppressor gene PTEN by epigenetic 
preventing or somatic mutations. In spite of the role of pAkt in HCC still more 
investigation, recent studies have suggested a worse estimate for tumors with activated 
Akt59.MTOR is consider as an important mediator of the PI3K-Akt pathway, which acts as 
a central regulator of cell growth and proliferation, by sensing nutritional status and 
allowing progression from G1 to S phase41. The mTOR pathway is activated in a subset of 
HCCs, and its blockade with rapamycin or everolimus inhibits growth in HCC cell lines, 
and in experimental models 42. Many novel compounds (MTOR inhibitor) are recently 
being tested in early clinical trials. These molecules (rapamycin and analogs) are already 
approved as immunosuppressive treatments after liver transplantation60. 
1.5.9  Relationship of Multiple-Drug Resistance and Chemotherapy  
        Cancer is a serious disease that ranks on the second position among diseases that lead 
to death, in 2015 have been found death of one person in every five or six people in the 
western countries. It is also responsible for 8.2 million of deaths around the world. Every 
year more than 14.1 million cancer cases are revealed, mainly in the developing countries. 
For more, people who live with cancer count more than 32.5 million61, 62. 
When the cancer cells start to be abnormally fast divided cancer is known as serious 
genetic disorder. So, if the abnormal divided cells untreated, it will affect the other tissues 
of the body and lead to death. The main available treatments of cancer are 
chemotherapeutic agents which can either stop or slow the abnormal fast division of the 
cells63,64. The major challenge associated with the available chemotherapeutic agents is the 
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drug resistance which involved with 30%- 80% of cancer patients65. Therefore, there is an 
urgent need to find a new agent to overcome the chemotherapeutic resistance. 
Drug resistance in cancer cells is not related to one anticancer drug, but the whole 
available chemotherapeutic agents within the same family can be influenced by the same 
mechanism. Some cancer cells that developed drug resistance can be resistance to other 
types of drugs that are different in their mechanism of action and structure. This process 
defined as multidrug resistance (MDR). This phenomenon might clarify the failure drug 
combination to overcome the cancer cell resistance66. There are two main clinical times of 
MDR; first one start  at the time of treatment and the second is already present at the time 
of the diagnosis67. 
Various biological reactions represent the first defense for the cells include:  
1. Activation of cellular elimination process, cellular uptake process and metabolic 
reactions to inactivate the drug process inside the cell, all of these processes will 
cause the decrease of the chemotherapy concentration inside the cell (Figure 
1.6)68,69.  
2. Changes of the drug delivery to the targeted tissues because of different reasons 
including poor pharmacokinetics profile of the drug such as absorption, 
distribution, metabolism and excretion (ADME)70, 71.  
3. Enhance the process of DNA repair71.  
4. Structural modification of the targeted tissues72.  
All the previous mechanism are extracellular factors that increase the cell anticancer drug 
resistance. However, the cellular factors that affect the drug presence inside the cell play a 
main role for the cell resistance to anticancer drugs through biochemical changes in the 
tumor cells and this process include transport-based MDR known as ATP-binding cassette 
(ABC). 
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Figure 1.6 Mechanism Involved in increase Drug Resistance towards cancer 
chemotherapeutic drugs. 
Different transporter proteins are located in the lipophilic membrane of the cell, 
which play essential role in the pharmacodynamics and pharmacokinetics of various drugs. 
Therefore, massive studies on the transporters have been conducted to identify their 
locations, functions, structures, selectivity and cellular distribution73. Cellular MDR 
decreases the intracellular concentration of the drugs by enhancing the ATP-dependent 
efflux pumps, which is one of the family membranes of ATP-binding cassette (ABC)74. 
ATP-binding cassette is considered as the largest transmembrane protein family that 
demonstrated wide range of specificity. There are about  49 known human ABC genes, 
which are categorized into 7 subfamilies starting with ABC and end with ABCG and the 
classification were relay on the arrangement of the domain and similarity of the 
sequence66.Many products resulted from the metabolic reactions, lipids and various types 
of chemotherapeutic agents are pumped out of the cells through ABC-transporter utilizing 
ATP-energy dependent movement processes75. The chemotherapeutic agents that 
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commonly affected by MDR process are hydrophobic containing drugs, natural products 
such as docetaxel and paclitaxel, anthracyclines (daunorubicin, doxorubicin), anti-
microtubule alkaloids (vincristine), antimetabolic agents (6-mercaptpurin, methotrexate, 
gemcitabine, fluorouracil), epipodophyllotoxin (teniposide and etoposide) and RNA 
elongation inhibitors (actinomycin-D)76,77. 
1.5.10  Role of ABC Transporters in Cancer Chemotherapy  
 Multidrug resistance protein 1 (MRP1)/ ABCC1, MRP2 and breast cancer 
resistance protein (BCRP)/ ABCG2/MXR/ABCP  are responsible for MDR78. These 
proteins play key role in recognition and transport of a large number of structurally diverse 
compounds. Many studies have shown that inhibiting these ABC transporters can prevent 
MDR79. The MRP subfamily is, the C subset of the ABC transporter superfamily and it is  
composed of thirteen members, and nine of these are primarily involved in MDR80. 
  Functional characterization, localization, and cloning studies have shown that, 
these nine MRPs have been established as ATP dependent efflux transporters for 
endogenous substances and xenobiotics. The other three members of the MRP subfamily, 
namely ABCC7/cystic fibrosis transmembrane conductance regulator (CFTR), 
ABCC8/sulfonylurea receptor 1 (SUR1), and ABCC9/SUR2, have no role in conferring 
MDR. The role of ABCC7 is to regulated chloride channel, whereas ABCC8 and ABCC9 
are intracellular ATP sensors and regulate the specific K+ channel permeability77. The nine 
main MRPs can be divided into two groups on the basis of structural topology. One has a 
common ABC transporter structure and is composed of two membrane spanning domains 
(MSD) with nucleotide binding domains (NBD1 and NBD2) in between (Figure 1.7)81. 
These can be referred to as short (MRPs) and include MRP4, MRP5, MRP8, and MRP9 
(ABCC4, 5, 11 and 13, respectively). The other group, which includes MRP1,2,3,6and7 
(ABCC1,2,3,6and7, respectively), have an additional MSD (MSD0) and are referred 
as(MRP)82.  
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Figure 1.7 The Location of short (MRP4, MRP5, MRP6, MRP8 and MRP9) and long form 
(MRP1, MRP2, MRP3, and MRP7). 
 
1.5.11  Natural products as potential source of biological agents: 
           Natural products are a good and affordable source for new drug entities. Different 
vaccines and biologics have been inspired from natural products structure. Around 48.6% 
of the anticancer drugs are natural products or derived from many natural products83.
 Later on, many advances in biological screening techniques have allowed the study 
of the biological mechanisms and chemical profiles of living systems, which has 
encouraged researchers to investigate the pharmacological effects of natural compounds84. 
Studies are done to clarify the natural products' synergistic impacts and their clinical effects 
on the individual body, which could help provide novel curative approaches to different 
diseases85 Including vinblastine, etoposide, paclitaxel, and camptothecin. Plants have been 
considered as a source for medicaments because of their availability and it was given either 
in a crude extract or a pure ingredients86. One of the most studied natural product that has 
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many biological activities is cucurbitacins87. 
1.5.11.1  Cucurbitacin 
            Cucurbitacins natural compounds that extracted mostly from the plant of 
Cucurbitaceae family such as Ecballium Elaterium, Genystlus keithii, Cayaponia Tayuya, 
Citrillus Colocynthic, Trichosanthes Kirilowii and Ecballium Elaterium85. Cucurbitacins 
are highly oxidized tetracyclic triterpenoid. They are characterized by their bitterness and 
toxicity88.  
 Isolation of cucurbitacin have been achieved from different parts of the plant, 
including the seed, roots, rhizomes and aerial parts of Cantaloupe, Watermelon, Pumpkin, 
Honeydew Melon, Spaghetti Squash and Crenshaw Melon89. Several studies have 
confirmed the medicinal activity of the cucurbitacins and their clinical effects. Until this 
time cucurbitacin are still used as a treatment in some parts such as Asia, Africa and South 
America. Many biological activities  have been associated  with cucurbitacins and their 
glycoside derivatives89,90. Recently, cucurbitacins B, C, Q, and E showed antiproliferative 
activity on 8 different cancer cell lines, such as HepG2, MDA-MB-468, MCF-7 and A549. 
Several  animal studies demonstrated that cucurbitacins anticancer activity through  
apoptosis stimulating activity  the inhibition of the Janus kinase (JAK), signaling marker 
and activator transcription3 (STAT3) signaling90,91. 
1.5.11.2  Structure of cucurbitacins 
           Cucurbitacins are tetracyclic triterpenoid steroidal carbon skeleton (Figure 1.8). It 
is believed that other cucurbitacins are derived mainly from the metabolism of cucurbitacin 
B or E by enzymatic reactions92. For example, the metabolism of cucurbitacin B produce 
cucurbitacin A, C, D, F, G and H, while cucurbitacin E metabolism gives cucurbitacin I, J, 
K, and L. In addition, cucurbitacin B and D can be reduced to 23, 24-dihydrocucurbitacin 
B or 23, 24-dihydrocucurbitacin D93. The presence of dimethyl group at C4, isopropyl 
group at C24 and unsaturated are considered as a unique feature for cucurbitacins. For 
more, there are methyl groups at C9, C13, C14 and C20. Cucurbitacins could be  exist in 
plants as glycosylated or nonglygosylated94. 
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 The cucurbitacins four-ring system similar to the structure of a steroid ring94.the 
Two common difference between cucurbitacins and steroids structures, are that 
cucurbitacins having a gem-dimethyl group at C-4 and a C-10 methyl in C-9. 
Cucurbitacins' main structures share common features, such as: 1) the double bond between 
C-6 and C-5; 2) a high level of oxidation due to the substitutions of many carbons (C-16, 
C-11, C-3, C-2) by oxygen atoms; 3) the presence of hydroxyl groups, α at C-16 and β at 
C-20 and C-25; and 4) α-β-unsaturated ketone in the side chain located at C-22, C-23 and 
11 C-24. an aromatic ring is a common feature in some of the cucurbitacin derivatives, 
such as Fevicordin A95. Additionally, cucurbitacins can be found as free glycone structures 
or glycosidic structures by a β-linkage to the hydroxyl moiety from monoside at C-2, C-3 
and C-25 or from bidesmosides at C-26 or C-2796. 
 
Figure 1.8 General structures of cucurbitacin and steroid. 
1.5.12  Biological activities of cucurbitacin: 
1.5.12.1 Cucurbitacins Activity as Anti-inflammatory Compounds 
           Cucurbitacins anti-inflammatory have been proven via targeting many biological 
targets to decrease the inflammation. The cyclooxygenase (COX) enzymes playing an 
important role in anti-inflammatory activity of cucurbitacins, especially cyclooxygenase2 
(COX-2). In comparing the non-steroidal anti-inflammatory drugs (NSAIDs) and 
cucurbitacins, the inhibitory rate for COX-2 by cucurbitacins is less than the NSAIDs; for 
example, at 100mM concentrated cucurbitacins B, D, E and I showed inhibitory rates of 
32, 29, 35 and 27%, respectively, compared to the COX-2 of NSAIDs such as Refeoxib, 
Ibuprofen and Naproxen. The same study has proved the selectivity of cucurbitacins 
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towards COX-2, since they do not show any activity on the cyclooxygenase-1 (COX-1) 
enzyme97.  
1.5.12.2  Cucurbitacins Effect on Filamentous-Actin 
            Many studies confirmed the activity of cucurbitacins E, I and B on the cytoskeleton, 
particularly on F-actin. One of these  studies proved that some cucurbitacins derivatives 
including cucurbitacin E, stimulate actin cytoskeleton disturbance98. This disturbance 
connected with the effect of cucurbitacins on the actin-proliferative action in prostate 
cancer cell line. One of the features  of cucurbitacin E is that it has a selective inhibition 
on F-actin depolymerization, but not on monomeric globular G-actin, by forming a 
covalent bond with CYS 257 amino acid residue99. 
1.5.12.3  Mitogen Activated Protein Kinase (MAPK) Pathway Activation by 
Cucurbitacins 
         MAPK pathway is considered one of the key parts in the cellular process, which has 
signaling transducing cascade including Ras/B-Raf/MEK/ERK (Fig1.5). A limited 
research studies have mentioned the potential biological activities of cucurbitacins 
targeting the MAPK pathway. Chean et al. confirmed that cucurbitacin B inhibits the 
STAT3 and RAS/B-Raf/MEK/ERK cell downstream signaling cascade using the K562 
leukemia cell line100. One more study has been done by Salama and Halaweish via Utilizing 
computational semi-flexible molecular docking, MTT cell viability assay and binding 
immune assay, demonstrated the ability of several types of cucurbitacins to target MAPK 
signaling pathway using mutant B-Raf cell lines101. 
1.5.12.4  Cucurbitacins as Potential Modulator for Epidermal Growth Factor Receptors 
(EGFR) 
            EGFR, in human cancer has been proven to be involved in the mutation and deletion 
of the cell upstream and downstream targets, which makes EGFR a promising biological 
target for different types of human cancer102. Hollbro et al confirmed that ErbB receptors, 
a member of the GFR family, are a promising targets for the treatment of different kinds 
of cancer103. The activation of EGFR and its downstream cascade has increased the survival 
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rate of patients in the late stages of hepatocellular carcinoma as reported by Liovet et al104.  
1.5.13  CUCUS-Inspired Estrone Analogs (CIEA)  
  Cucurbitacins is a group of steroidal-triterpene tetracyclic natural products, which 
reported for their anti-cancer activities105. However, cucurbitacins have been reported for 
their potent activities, synthesis of these compounds is challenging due to the complexity 
of the carbon skeleton and functionalities of these compounds. Recently many studies in 
Halaweish’s group started to study cucurbitacins targeting epidermal growth factor 
receptor (EGFR)100. 
 Molecular modeling and docking methods were applied to find potential affinity 
between cucurbitacins and EGFR along with downstream proteins cascade including Ras, 
Raf, MEK and ERK (Figure1.4). In addition, more studies such as cytotoxicity, western 
blot and ELISA were used to prove the molecular docking studies results. Cucurbitacins 
confirmed to have activities against different cancer cell lines; however, their activities 
don’t show specificity or selectivity toward their biological targets. Gastrointestinal 
toxicity is one of the side effects involved with cucurbitacins subjections due to their 
cellular activations106. Strong cytotoxicity of cucurbitacins in in-vivo model toward renal 
carcinoma demonstrated narrow safety and have been withdrawn from preclinical studies 
due to their fatal activity107.The broad biological activities of cucurbitacins, non-selectivity 
and toxicities are due to their complex chemical structure108. 
 Cucurbitacins inspired estrone compounds (CIEA) was accomplished in 
Halaweish’s group targeting melanoma109. The success in Halaweish’s group of utilizing 
the molecular docking inspired us to model novel analogues to target hepatocellular 
carcinoma (HCC). 
Due to the similarity in chemical structure, particularly the cyclopentane and the 
four-ring system, redesigning and mimicking cucurbitacins utilizing steroids may improve 
their biological activities and selectivity. Cucurbitacins side chain, which contain α-β-
unsaturated ketone, is significant pharmacophore for their biological activities. In addition, 
the presence of C-16 hydroxyl group increased the chance of forming H-bond with C-24 
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ketone, which may enhance the electrophilicity of the α-β-unsaturated ketone110,111 .  
1.5.14 Targeting Epidermal Growth Factor Receptor (EGFR): 
            Many studies have been done on cucurbitacins as promising EGFR inhibitors is not 
favorable sometimes due to availability and limitation. This but has encouraged us to 
identify the most significant pharmacophores of cucurbitacins in order to synthetically 
modify their main skeleton to increase the selectivity toward EGFR and minimized their 
undesirable side effects101.Limited researches and studies on the structure modifications of 
cucurbitacins have been conducted including quantitative structure activity relationship 
(QSAR) studies of semi synthetic of cucurbitacins by Bartalis and Halaweish111.  
Several CIEA have been synthesized by small modifications at C-2 of estrone main 
structure by installing sulfamate moiety, changes the biological properties of the estrone 
dramatically by blocking the estrogenic activity and performing anti-proliferative activity 
in breast cancer cells112. In 2016, Bodnar et al, proved that triazole substitution at C-3 
position of estrone enhanced the biological activity as anti-cancer with IC50=0.3-0.9μM 
97. Ahmed et al. 2014 confirmed a potent inhibitory activity of MAPK pathway toward 
treatment of melanoma by a substitution on C-17 of the estrone skeleton structure109. 
Subsequently, by utilizing molecular modeling, series of modified estrone at C-25, C-17, 
C-16, C-11 and C-3 positions were designed and developed to target Epidermal Growth 
Factor Receptor (EGFR) toward treatment of Hepatocellular Carcinoma (HCC). 
 
Figure 1.9 Significant positions for biological activities in estrone main structure. 
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 In our group the molecular docking result on the crystal structure of EGFR showed 
an outstanding binding affinity with the CUCUS-inspired estrone analogues containing 
various functional groups compare to the known EGFR inhibitor, Erlotinib. Modified 
estrone at C-17 with isopropanol enon side chain, methoxy group at C-3 and double bond  
at C-16 and C-17 position such as MMA102 and MMA132 demonstrated various binding 
mods with EGFR binding pocket. MMA132 and MMA102  
 
  MMA102 and MMA132 are diastereomers to each other and showed varieties in 
the binding mode with the receptor. MMA132, which possess the stereochemistry of 
cucurbitacin D side chain, showed an outstanding binding mode with EGFR by forming 
H-bond with MET:769: A, which is same amino acids residues that erlotinib binds to in 
EGFR to induce anti-cancer activity by H bonding with the same amino acid MET:769-A; 
also, MMA132 perform hydrophobic interactions with the amino acids residues inside the 
binding pocket. While MMA102 which has the opposite stereochemistry of cucurbitacin 
D demonstrated less binding affinity toward the EGFR binding site only with a 
hydrophobic interaction mode with the EGFR binding pocket. This result proved the 
significant of assembling the enone side chain with the stereochemistry of cucurbitacin D 
(Figure 1.10). 
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Figure 1.10 Visual representation of A) MMA102 (orange) B) MMA-132 (blue) in the 
EGFR ATP binding site along with Erlotinib (purple). 
 
1.6 Project Objectives:  
 This project is focused on using cucurbitacins inspired analog as a semi-synthesized 
natural product that has inhibitory activity toward the epidermal growth factor receptor 
(EGFR) and develop it as drug candidates for the treatment of hepatocellular carcinoma 
(HCC). No many studies have defined the activity of cucurbitacins toward EGFR in HCC 
cell line. In addition, no cucurbitacin-like compounds have been synthesized and 
28 
 
 
 
biologically evaluated targeting HCC. The main objectives of this project are: 
      Aim1: Studying the cytotoxicity of natural products or semisynthesized natural   
products against Hepatocellular Carcinoma cell line 
  Aim2: Study of the effect of CIEA chemosensitization of HCC/HepG2 resistance cell line 
to chemotherapy drugs (Erlotinib)  
     Aim3: Study the role of multidrug resistance associated protein (MRPs) against 
sensitive HEPG2 cell line and resistant HEPG2R cell line. 
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2. Chapter Two 
Study the cytotoxicity of natural products or semi-synthesized natural products 
against hepatocellular carcinoma cell line  
2.1 Introduction 
Many natural products, biological compounds, total synthesis or vaccines are used 
as the main sources of small organic molecules which know as a drug drugs1. Since the 
ancient times, natural products play an important role as resource of medicines. For 
instance, some herbs used to be chewing to decrease the pain and some of them used to be 
wrapped around wounds to heal it. Using natural products to treat diseases and injuries 
known as folk medicine2. Recently, the large improve in developing materials to study the 
biological mechanism of all new chemical entities, encouraged researchers to investigate 
more in the pharmacological effects of natural compounds to clarify their synergistic 
impact and their clinical effects on the body. Natural compounds could be providing novel 
medicinal approaches toward a variety of diseases, cancer one of them3.  
Hepatocellular carcinoma (HCC) is one of the highest cause of mortality and the 
third causing of death worldwide4, 5. It has been reported that Asia and Africa have the 
highest report of HCC with high incidence among men. HCC was somewhat rare in the 
United States compare to the other countries; however, recently it became one of the main 
cause of death in the United States6. HCC is a continuous and slowly progressing disease 
that is generally associated with other factors such as cirrhosis, hepatitis C virus (HCV), 
and hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and 
alcoholic consumption)6, 7. Many therapeutic options are available now for HCC such as 
local ablation therapy, surgical resection and liver transplantation8. However, these options 
are not viable for late diagnosed patients. Chemotherapeutic drugs such as Erlotinib and 
Sorafenib are common treatments for HCC9. In addition, drugs resistance and undesirable 
side effects are the most challenge problems associated with these chemotherapy drugs10. 
Therefore, there is an urgent need to find a new drug candidate to overcome these problems. 
HCC molecular pathogenesis is classified into two main complex mechanisms; 1) 
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mutation, which happen in some tumor suppress genes or oncogenes; 2) some diseases or 
metabolic disorder such as hepatitis infection, metabolic effects (such as obesity, insulin 
resistance, type-2 diabetes), toxin (such as alcohol) that cause tissue damage which lead to 
cirrhosis11, 12. Both of these mechanisms have been related with irregularity in different cell 
signaling pathways that continue the process of carcinogenic results. From a therapeutic 
view, all of these signaling pathways are very significant to treat HCC. Consequently, 
growth factors-mediated, angiogenic signaling, epidermal growth factor (EGFR), vascular 
endothelial growth factor (VEGF),  hepatocyte growth factor (HGF), insulin-like growth 
factor (IGF), platelet-derived growth factor (PDGF), and the mitogen activated protein 
kinase (MAPK) pathways are the most distinguished targets for treating HCC due to their 
noticeable overexpression during the disease Figure 2.113,14. 
 
Figure 2.1 Signaling pathway/molecular targets and new targeted agents under 
development in hepatocellular carcinoma. 
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Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) figure 3.2 is one of 
the tyrosine kinases that has been confirmed in many studies as a promising target for the 
treatment of different carcinoma including HCC15. EGFR, which is also known as ErbB1, 
is a member of family of growth factor receptors including ErbB2, ErbB3 and ErbB4. 
Paracrine or juxtracrine extracellular ligand binding such as epidermal growth factor (EGF) 
and transforming growth factor (TGF)-α stimulate the EGFR, which lead to hetro- or homo 
dimerization and conformational change that activate the tyrosine kinase and allow 
autophosphorylation16, 17 .The phosphorylation  is the key role for this signaling pathway 
for cancer treatment. When  the phosphorylation  occurs, number of signaling pathways 
activated leading to cancer cell invasions, proliferation, metastasis, inhibitory of apoptosis 
and angiogenesis (figure 2.2)18, 19. Therefore, inhibition of EGFR-TK signaling cascades 
provides an approach for the treatment of hepatocellular carcinoma (HCC). 
 
Figure 2.2 EGFR signaling pathway in HCC.  
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Cucurbitacins (CUCS) (Figure 2.3) are natural products extracted from plant of 
Cucurbitacea family such as Gonystylus keithii, Cayaponia tayu, and Citrillus colcynte. 
Cucurbitacins plant family first used in folk medicine due its biological significant and 
activity as anti-inflammatory agents. There are many types of cucurbitacins classified as 
following; A, B, C, D, and E, to T. In addition, hundreds of cucurbitacins derivatives have 
been isolated and identified some20. They have been used for treatment of different diseases 
such as chronic hepatitis, liver cirrhosis, jaundice, dyspepsia, inflammation and cancer21. 
Recently, many studies have shown significant activities of CUCS as potential candidates 
for treatment of hepatocellular carcinoma (HCC)22. Current knowledge of molecular 
targets and singling pathways of different types of cancers provide a clear understanding 
of tumor cell regulation, which in turn paved the way to synthesis promising potential drug 
candidates. 
 
Figure 2.3 Structures of Cucurbitacins and Starting Material Estrone. 
CUCS demonstrated a wide range of biological activities due to their cytotoxicity 
on cancer cells and their potency on different biological pathways. These biological 
activities nominate CUCS as a potential drug that targeting multiple types of cancer23. 
Cucurbitacin D, isolated from Cucurbita Texan, and 3-epi-isocucurbitacin D prevent client 
maturation without induction of the HSR. Cucurbitacin D also disrupted interactions 
between Hsp90 and two cochaperones, Cdc37 and p2324. 
To avoid the undesirable adverse effects of the natural products and increase their 
selectivity, many structural modifications to their structure causes the improvement in their 
efficiency25. Therefore, the identification of the most significant pharmacophore of the 
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natural products is essential to conduct structural modifications. 
 What make the CUCS interested in our group is that CUCS has tetracyclic moiety, 
they are very similar to that of steroids (Fig. 2.3). However, they in  fact that C-10 methyl 
is located at C-9, possess a gem-dimethyl group at C-4 and the configuration of ring B and 
ring C26 . Due to this the similarity between the core structures of CUCS and steroids, the 
concept of hybrid drug design were used to install the essential pharmacophore of the 
CUCS into the steroid structure as promising alternative for the complicated functionalized 
structure of the CUCS27, 28 . Specifically, using the estrone skeleton as a starting material 
to install different functional moieties including the CUCS side chain and other 
functionalities has been done by Kopel et al 27. Furthermore, adding various moieties to the 
estrone skeleton structure at C-3, such as methoxy and hydroxyl groups, beside the CUCS 
side chain at C-17 in the presence of double bond at C16-C17 demonstrate an increase in 
the biological activity of these series of compounds toward several targets. The presence 
of the double bond at C16-C17 changed the conformation of estrone CUCS-like 
compounds which improves its binding affinity towards the EGFR-TK29.  
 In our group novel CUCUS-inspired estrone analogs with aliphatic side chain such 
as MMA102, MMA132 were synthesized by installing the CUCS side chain at C-16 and 
C17 of estrone scaffold. Those compounds demonstrated a very promising binding affinity 
by making a hydrophobic interaction as in MMA102, which has the opposite 
stereochemistry of cucurbitacin D side chain with amino acids residues of the crystal 
structure of EGFR binding pocket; while analogue MMA132, which possess the exact 
stereochemistry of the side chain of cucurbitacin D, demonstrated an outstanding binding 
affinity through hydrophobic interaction with amino acids residues of the EGFR along H-
bond with MET: 796:A, which is the same amino acid as that of Erlotinib make H-bond 
with and responsible for its anti-cancer activity (Figure 2.4).  
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Figure 2.4 Chemical structures of MMA132 and MMA102. 
 Chemotherapeutic agents, such as erlotinib and lapatinib, have been shown as 
potent inhibitor against EGFR by inhibiting its phosphorylation; these are known 
chemotherapeutic agents for the treatment of HCC and other types of cancer. Erlotinib 
(Tarceva) is a very active and selective inhibitor of the EGRF-TK protein. It has an 
advantage over most of the anti-cancer agents in that it can be taken orally, inhibits cellular 
proliferation and causes cell cycle arrest at the G1 phase. In addition, it has been approved 
as an active drug for pancreatic and lung cancer by the FDA although is still in Phase II 
clinical trials as an anti-cancer drug for HCC30.  
2.2 Induction of apoptosis by Erlotinib  
  Apoptosis plays important role in normal tissue development and maintaining the 
hemostasis31. Therefore any mutation or any defect in this pathways leads to different 
diseases such as degenerative and autoimmune diseases32. Carl Vogt 184233 discovered it  
and in 1965   Lockshin and Williams introduced the term programmed cell death34. Only 
after a decade, the term apoptosis was introduced by Kerr et al35. , Two pathways, namely 
intrinsic and extrinsic pathway regulate and induce apoptosis (Figure 2.9)36. Caspases 
regulates both pathways, which are synthesized as inactive enzymes and converted to 
active enzyme by cleavage. The active caspases cleaves different target proteins that are 
necessary in DNA repair and cytoskeleton assembly ultimately causing  cell death37. The 
caspases are classified into two categories, initiators and executioners. Binding of the 
ligand such as Fas ligand (FasL) and tumor necrosis factor (TNF) to the death receptor 
(DR)38 causes the induction of extrinsic pathway. DRs include TNF-R1, Fas-Apo1, DR3, 
TNF-related apoptosis-inducing ligand receptor-1 (TRAIL-1), TRAIL-2 and DR6. The 
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death receptors comprise of extracellular cysteine rich domain (CRD) and an intracellular 
death domain (DD)39. Upon ligand binding, the receptor undergoes trimerization leading 
to the recruitment of initiator caspases 8 and 10 and Fas-associated death domain (FADD) 
to the receptor to form the death inducing signal complex (DISC) to amplify the apoptotic 
signal. In addition, the initiator caspases undergo autocatalytic activation which activate 
the effector caspases 3, 6 and/or 732. Erlotinib induces the apoptosis through the caspase-3 
pathway. Erlotinib was confirmed that induced caspase-3 activity increased dose-
dependently to 300%40. In the cytoplasm which forms apoptosome complex by binding to 
Apaf-1 and procaspase 9. This apopotosome complex activate caspase 9 by auto cleavage. 
The cleaved caspase 9 cleaves procaspase 3 which is the executioner caspase leading to the 
proteolytic cleavage of different cellular proteins inducing apoptosis41. 
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Figure 2.5 Intrinsic and extrinsic apoptotic pathway. 
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Aim of the Study: Therefore, understanding the antiproliferative activity of Erlotinib 
paved the way for studying the antiproliferative mechanism pf potential drug 
candidate.   The aim of this study to investigate the potential anti-proliferative activity 
of CIEA as potential drug candidate for treatment of HCC. 
2.3 Erlotinib and cell cycle regulation 
  Cell cycle is divided into 4 sequential stages (Figure 2.5)42.  Cells need longer time 
to prepare for DNA replication in S phase rather than doubling their content from protein 
and organelles. The cell prepares itself for replication by monitoring the environment and 
building their proteins in the two gaps G1 and G2., Depending on the external conditions 
and the signals coming from other cells the length of the G1 phase varies from days, weeks 
or even years. Cells can enter a resting phase called G0 if the external environment is not 
favorable. The cells can enter the S phase once the condition is favorable again. G2 phase  
plays important role by checking the quality of replicated DNA, and synthesizing  the 
proteins required for commitment of mitosis (M phase)43, 44. 
  DNA damage result in activation of  the cell cycle checkpoints by cyclin-dependent 
kinases leading to the cell cycle arrest at G1, S and G2/M phase
45 . The antiproliferative 
potency of Erlotinib in hepatocellular carcinoma cells contributed   to the induction of cell 
cycle arrest at G1/G0 phase of the cell cycle , that way decreasing the proportion of cells in 
S-phase40. 
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Figure 2.6 The cell cycle is divided into four phases. 
2.4 ERK MAP kinase in G1 cell cycle progression and cancer 
  One of the key process that convey signals from the cell surface to the nucleus is 
the Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein (MAP) 
kinase signaling pathway. In the Ras/ERK signaling pathway a variety of extracellular 
stimuli induce sequential activation of mainly three protein kinases; Raf, MEK, and ERK 
(Figure 2.6)46. ERK is activated by MEK via phosphorylation on both threonine and 
tyrosine residues in the TEY sequence. Activated ERK, in turn phosphorylates both 
cytoplasmic and nuclear substrates, including many enzymes, cytoskeletal proteins and 
transcription factors. Recently, many studies have identified several scaffold proteins and 
inhibitors proteins that have potential role in Ras/ERK signaling pathway. These proteins 
can modulate the duration, magnitude, and subcellular location of ERK activity which 
provide variations in ERK signaling47, 48. There is multiple research which suggests that 
the differences in ERK activity generate variations in signaling outputs that will cause 
regulation of the cell fate decisions. In addition, interaction with other pathways could also 
be crucial for determining signaling specificity. The role of Ras/ERK signaling pathway in 
cell cycle progression in G1 phase and cell proliferation is well established
49. 
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Figure 2.7 The Ras/extracellular-signal-regulated kinase (ERK) signaling pathway. 
 In Cell cycle progression from G0/G1 to S phase requires  activation of the Ras/ERK 
signaling pathway  which is related to cyclin D induction and consequent retinoblastoma 
(Rb) phosphorylation50,51. ERK is phosphorylated and activated by many external stimuli 
like growth factors which then translocate from the cytoplasm later to the nucleus, where 
ERK phosphorylates and activates several nuclear ERK targets, including transcription 
factors such as Elk-1. Therefore, ERK is responsible for the expression of the immediate 
early genes, such as c-fos52. The expression of the immediate early genes in turn regulates 
subsequent induction of the delayed early genes, including a first class of G1 cyclins, cyclin 
D. Upregulation of cyclin D expression results in upregulation of the cyclin D–CDK4/6 
complex. Activation of cyclin D–CDK4/6 kinase activity leads to phosphorylation and 
inactivation of Rb, which then activates the E2F family of transcription factors and induces 
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expression of target genes, including a second class of G1 cyclins, cyclin E53. As a result 
of activation cyclin E–CDK2 kinase, it will lead to further phosphorylation and inactivation 
of Rb, thus further increase the activity of the E2F family. This positive feedback leads to 
the synthesis of proteins required for S phase entry (Figure 2.7)54,55. Therefore, in response 
to growth factor stimulation, ERK triggers these sequential events, including sequential 
induction of a number of genes, and thereby causes S phase entry. 
 
Figure 2.8 Regulation of G1 cell cycle progression through ERK signaling. 
 Recently it has been suggested that for inducing S phase entry of quiescent 
fibroblastic cells sustained ERK activation, but not transient activation56, 57. It is necessary 
to sustain the ERK activity for approximately 2 or 3 h before the onset of S phase58.Thus, 
through ERK activity is a key factor for keeping G1 phase progression. ERK activation can 
induce cyclin D expression several hours after growth factor stimulation59.  More recently, 
Yamamoto et al. from a Genome-wide analyses of transcriptional programs in cell cycle 
progression from G0/G1 to S phase have shown that in addition to ERK-dependent 
upregulated genes, there are also ERK-dependent downregulated genes60. However, the 
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expression level of most of these ERK-dependent downregulated genes is maintained at a 
lower level throughout G1 phase, and the decreased expression levels return to the original 
levels rapidly if ERK inactivation occurs. It is to be noted that these  ERK-dependent 
downregulated genes are known antiproliferative genes until the onset of S phase to allow 
successful G1 phase progression (Figure 2.8)46. In addition to the mitogenic signals, the 
cells also receive varied stimuli such as environmental stresses that induce transient ERK 
activation. Transient ERK activation unable to induce sustained downregulation of 
antiproliferative genes, therefore these inappropriate stimuli do not cause cell proliferation. 
Thus, this mechanism  ensures prevention of inappropriate stimuli from causing cell cycle 
progression46. 
 
Figure 2.9 Role of ERK-dependent downregulation of antiproliferative genes in G1 phase 
progression. 
2.5 Materials and Methods 
2.5.1 Hepatocellular carcinoma cell lines and the drugs 
  The human hepatoma cells line, HepG2 were received from ATCC. The cells were 
maintained in EMEM (Eagle's Minimum Essential Medium) from (ATCC) with L-
Glutamine supplemented with 10% fetal bovine serum (FBS) (Atlanta biologicals) and 1% 
penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Corning) at 37°C, 5% CO2. The 
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passage number range for cells line maintained between 4-13. The cells were cultured in75 
cm2 cell culture flask61 . 
2.5.2 Cytotoxicity assay 
  The sensitive hepatoma cells (HepG2) were seeded in 96-well plate as 5*104 
cells/mL (100 μL/well). A serial dilution of CIEA compounds were added after overnight 
incubation of the cells at 37°C and 5% CO2. DMSO (Acros Organics) was used as a control 
(0.1 %). The cells were incubated with the compounds for 48 hrs. After that 15 μL of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma Aldrich) (5 
mg/mL PBS) were added to each well and the plate was incubated for another 4 hrs. The 
formazan crystals were solubilized by 100 μL acidified SDS solution (10% SDS/0.01 N 
HCl) (Fisher BioReagents). The absorbance was measured after 14 hrs of incubation at 
37°C and 5% CO2 at 570 nm by Hidex Sense Microplate readers62 
2.5.3 Cell cycle analysis 
The study of   cellular DNA content and cell cycle distribution are useful to detect 
variations of growth patterns due to a variety of physical, chemical, or biological means, 
to detect  apoptosis, and to study tumor behavior and suppressor gene mechanisms63. In a 
given population, cells are distributed among three major phases of cell cycle: G0/G1 phase 
(one set of paired chromosomes per cell), S phase (DNA synthesis with variable amount 
of DNA), and G2/M phase (two sets of paired chromosomes per cell, prior to cell division). 
DNA content can be measured by using fluorescent technique , DNA-selective stains that 
exhibit emission signals proportional to DNA mass64. Flow cytometric analysis of these 
stained populations is then used to produce a frequency histogram that reveals the various 
cell cycle phases. This analysis is typically performed on permeabilized or fixed cells using 
a cell-impermeant nucleic acid stain. But it is also possible using live cells and a cell-
permeant nucleic acid stain. While the choices for fixed cell staining are varied, there are 
only a few examples of useful cell-permeant nucleic acid stains. The Vybrant® 
DyeCycle™ Green and Orange stains are DNA-selective, cell membrane permeant, and 
nonfluorescent stains for DNA content analysis in living cells. The Vybrant® DyeCycle™ 
Green and Orange stains (green is the one that was used in this study) are fluorescent upon 
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binding to double-stranded DNA. These stains take advantage of the commonly available 
488 nm excitation source, placing cell cycle studies on live cells within reach of all flow 
cytomatrices. Vybrant® DyeCycle™ Green stain is excited at 488 nm with emission ~520 
nm65.  
Method A: 
 The cells were seeded as 2.5*105 cells/mL in a 6-well plate (2 mL/well) and 
allowed to adhere overnight at 37°C and 5% CO2. The cells were either incubated with 
different concentrations of MMA132 (1, 2, or 4 μM)  and MMA102 ( 1.5, 3,and 6 μM )for 
24 hrs .The cells were washed twice with ice-cold 1X PBS (Hyclone™ L aboratories , 
Inc)and collected after trypsinzatio66. The cell pellet was washed two times with ice-cold 
1X PBS and fixed with ice-cold 70% ethanol overnight at -20°C. After that, the cells were 
washed once with ice-cold PBS and the second wash was done with ice-cold PBS-2% FBS. 
The cell pellet was re-suspended in 500 μL propidium iodide (PI)/RNase staining 
solution(BD Biosciences) for 15 min at room temperature (RT) in the dark and analyzed 
within 1 hr by (BD Accuri C6; Becton-Dickinson, Mountain View,CA)67. 
Method B: 
 According manufacturer protocol6817617667676767174, Cells were seeded into six-well 
plates at a concentration of 300,000 cells/ well and allowed to attach in culture overnight, 
then treated with IC50 values of compounds or positive control (Erlotinib) for 48 h. 
Afterwards, cells were washed with PBS and harvested. Cell cycle analysis was 
investigated in accordance with the manufacturers protocol with slight modification. 
Briefly, Vybrant® DyeCycle™ Green Stain (Thermo Fisher Scientific) was added to 1 ml 
of cell suspension at a final concentration of 0.0625 μM. After 45 minutes of incubation at 
37˚C, the samples were analyzed by flow cytometry and compared to DMSO-treated cells. 
All these experiments were performed on BD Accuri™ C6 flow cytometer (BD 
Biosciences, San Jose, CA, USA) using BD Accuri™ C6 software, version 1.0. 
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2.5.4 Caspases 3/7 detection 
  Effect of MMA132 treatment on the expression level of caspase 3 and 9. Cells were 
treated with 2 µM of MMA132 at different time points (1hr, 24hr, 48hr). β actin 
(ThermoFisher Scientific) was used as a positive control. The apoptotic effect of MMA132 
was confirmed by measuring the level of activated caspase 3 and 9 (Santa Cruz 
Biotechnology ) and PARP-169. 
2.5.5 Cell Migration (Wound Healing Assay)  
  The cells were seeded into 24-well tissue culture plate at a density that after 24 h of 
growth, they should reach ~70-80% confluence as a monolayer. By a new 1 ml pipette tip 
the well was gently and slowly scratched across the center. While scratching across the 
surface of the well, the long-axial of the tip was always perpendicular to the bottom of the 
well. The resulting gap distance therefore equals to the outer diameter of the end of the 
tip. After scratching, gently the wells were washed twice with cold 1X PBS to remove the 
detached cells.  The cells were either incubated with of MMA132 (2μM) and MMA102 
(3μM) for different time points (zero time, 1hr, 24hrs, and 48 hrs). The photos for the 
monolayer and cell movement were taken by a microscope at different time points. The 
gap distance can be quantitatively evaluated using ImageJ software70. 
2.5.6 Western blot analysis 
 The HepG2 protein lysate and western blot method was prepared and done 
according to El-senduny et al71.    HepG2 cells were treated with 2 µM and 3 µM of 
MMA132 and MMA102 respectively, and incubated for 1, 2, 4, 8, 24, 48 hrs. Briefly, cells 
were lysed with 1X RIPA buffer containing protease and phosphatase inhibitors. The BCA 
protein assay was used to quantify total protein concentration. An amount of 20 µg was 
loaded onto 10% SDSPAGE (ERK, pERK, MEK, pMEK, RAF, pRAF) and 8% SDSPAGE 
(EGFR, pEGFR) per well. The protein was transferred onto 0.45micron nitrocellulose 
membrane and blocked with 5% BSA, and subsequently incubated with ERK, pERK, 
MEK, pMEK, RAF, pRAF and EGFR, pEGFR primary antibodies overnight at 4°C. The 
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The 
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive 
control. 
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2.6 Results  
2.6.1 Anti-proliferation and Cytotoxicity Effect of CIEA to HepG2 Cell Line  
 To determine the anti-proliferation activity of CIEA on the HepG2 cell line, the 
cells were treated with tested compounds for 48 hrs and viability percentage was 
determined by MTT assay. Figure 1-10a and b show the cytotoxic effects of the CIEA on 
HepG2 cell lines. Table 1-3 summarizes the IC50 values of each CIEA as the most active 
compound against HepG2 cell lines. The anti-proliferation activity of the synthesized 
CIEA using MTT cell viability assay starting with compounds that have R-configuration 
showed that six CIEA have potent inhibitory activities on HepG2 cell line such as 
MMA132, MMA102, MMA290, MMA245, MMA265, and MMA240 compare to the 
standard Erlotinib with 25 µM. (Figure 2.10). 
In this study, MMA132 and MMA102 were chosen for further investigation 
because they are the most cytotoxic CIEA with 12 times activity more than that of Erlotinib 
(Figure 2.11).  
 
 
Figure 2.10 IC50 curves for MMA132, MMA102 compounds and Erlotinib on HepG2 cell 
line compared to DMSO control. 
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Figure 2.11 Cytotoxicity of CIEA on the HepG2 cell. 
 
Table 2.1 Anti-proliferation results against HepG2 cell line. 
CIEA IC50 µM 
Erlotinib* 25±0.02 
MMA132 2±0.01 
MMA128 25±0.2 
MMA265 16±0.05 
MMA240 13±0.01 
MMA305 29±0.4 
MMA102 3±0.2 
MMA287 25±0.4 
MMA290 6±0.01 
MMA245 3±0.02 
                                             * = Reference drug 
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2.6.2 MMA132 and MMA102 effect on cell cycle distribution 
 The HepG2 cells were incubated with different concentrations of MMA132 (1 µM, 
2 µM and 4 µM) and MMA102 (1.5 µM, 3 µM, and 6 µM) for 24 hrs then the DNA content 
was quantified in each phase of the cell cycle. The cells treated with MMA132 were 
arrested permanently at G1 phase, even at 1/2 its IC50 value (Figure 2.12).  Cells treated 
with different concentration of MMA102 were stopped at G1 phase, after increase the 
concentration to 6 µM, the cells arrested at G2 phase (Figure 2.14). Cycle arrested at G1 
phase was confirmed by detection of ELK/pELK level in the cell lysate by western blot. 
The level of pElk was slightly decreased (Figure 2.16). Elk one of ERK signaling pathway 
transcription factors, which plays a vital  role  to G1 regulation53.  
 
Figure 2.12 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. (A) Control 
DMSO. (B) 1µM MMA132. (C) 2 µM MMA132. (D) 4µM h and cell cycle analysis was 
performed as described in Materials and methods. The data are shown the percentages of 
cells in the G1, G2 and S phase. The histograms were analyzed to determine the percentage 
of cells in each phase of the cell. 
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Figure 2.13 Histogram showing the G1 percentage on HepG2 cell line treated with 
MMA132 
 
Figure 2.14 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. Cells were 
treated with different concentration of MMA102 (1.5 µM, 3 µM and 6 µM) respectively 
compared to DMSO control. The data are shown the percentages of cells in the G1, G2 and 
S phase. The histograms were analyzed to determine the percentage of cells in each phase  
of the cell cycle.  
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Figure2.15 Histogram showing the G1 percentage on HePG2 cell line treated with 
MMA102. 
 
Figure 2.16 Effects of MMA132 and MMA102 on ELK activation. Western blot analysis 
of the ELK1; (A) ELK phosphorylation inhibited and change the expression after 24 hrs 
which is related to G1 cell-cycle arrested by MMA132. (B) Effect of MMA102 on 
ELK/pElk. 
2.6.3 Effect of MMA132 and MMA102 on Cell Migration   
   HepG2 cells were incubated with 2 μm MMA132, 3 μM MMA102, 25 μM 
Erlotinib, 0.01% DMSO as a control. Cells were incubated with different treatment. 
Pictures were taken for the monolayer on microscope (LEICA DMI 400 B) at different 
time points (0, 1 hrs, 24 hrs, 48 hrs). The images showed that HepG2 cell can migrate into 
the scratched space in ~24 hours (Figure 2.17). With 2 μm MMA132, 3 μM MMA102 and 
25 μm Erlotinib treatment, the wound was still open after 24 hours indicating that inhibit 
cell migration or invasion compared to DMSO (control) by MMA132, MMA102 and 
Erlotinib. Consistent with these results, the ‘wound-healing’ assays show that parental cells 
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fill the gap completely by 48 hrs with DMSO and the wound was completely healed. By 
contrast, gap filling MMA102 and Erlotinib cells was much slower after 48 hrs, in addition 
MMA132 was inhibited cell migration 100%.  
 
Figure 2.17 MMA132, MMA102 and Erlotinib inhibit cell migration in wound-healing 
assays and the migration of cells in the open space was observed under a phase-contrast 
microscope (200) at the indicated times. 
 
2.6.4 Study the effect of MMA132 on apoptosis 
 Effect of MMA132 treatment on the expression level of caspase 3 and 9 was 
investigated. HepG2 were treated with 2 µM of MMA132 at different time points (1 hrs, 
24 hrs, 48 hrs) and β-actin was used as a positive control. The apoptotic effect of MMA132 
was demonstrated by measuring the level of activated caspase 3 and 9. Cells treated with 
MMA132 induced the caspase 9 level after 24 hrs compared to loading control β-Actin. 
Also, there is an increase in the caspase 3 level which was confirmed by inhibition of 
PARP. Moreover, it was a significant increase in the levels of both caspases 3 and 9 
compared to cleaved ones and inhibited the PARP level which is considered as an indicator 
for stopping the DNA damage repair which controls the apoptosis (Figure 2.18). 
63 
 
 
 
 
 
Figure 2.18 Effect of MMA132 treatment on the expression level of pro- and anti-
apoptotic proteins. The cells were treated with 2 µM concentrations for 1, 24 and 48 hrs. 
β-Actin was used as a loading control. PARP; poly ADP ribose polymerase, Caspase 3 and 
Caspase 9. 
 
 
Figure 2.19 Histogram showing the inducing of apoptosis by MMA132 
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2.6.5 Mechanism of cytotoxic and synergetic effects 
   The vital role of (EGFR) in tumor proliferation and its overexpression in HCCs 
have provided the rationale for targeting and interrupting this key signaling network. EGFR 
blockade through monoclonal antibodies and tyrosine kinase inhibitors has translated into 
promising evidence of clinical benefit in many types of cancer HCC one of them. EGFR is 
expressed in a high proportion of HCCs, and EGFR-inhibitors, such as Erlotinib which has 
been shown to inhibit HCC growth and metastasis formation in vitro and in vivo72. So, 
that’s why is urgently needed to understand the mechanism of RGFR signaling pathway. 
 The level EGFR/pEGFR, B-RAF/pB-RAF, MEK/pMEK, and ERK/pERK were 
detected after treatment of compounds MMA132 and MMA102 with 2 μM and 3 μM, 
respectively. MMA132 and MMA102 showed effect phosphorylation forms of RGFR 
signaling pathway. It was found that the phosphorylation level of EGFR was decreased 
after 48 hrs treatment with MMA132 by 90%. MMA102 inhibited p-EGFR level after 2 
hrs of treatment. In contrast, MMA132 showed only slightly effect at pB-RAF after 24 hrs 
while MMA102 decreased phosphorylation level of B-RAF after 8 hrs compared to loading 
control β-Actin. Moreover, the level of ERK, MEK and their phosphorylated forms were 
detected. Both MMA132 and MMA102 Leads to decrease in the level of phosphorylated 
ERK1/2 and MEK (Figure 2.20) and (Figure 2.22). 
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Figure 2.20 Changes in the expression level of EGFR signaling proteins by MMA132. 
HepG2 cells were treated with the indicated time points of 2 μM of MMA132. β-Actin was 
used as loading control.  
 
Figure 2.21 Histogram presented the inhibition of EGFRE by MMA132 on HepG2 cell 
line. 
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Figure 2.22 Changes in the expression level of EGFR   proteins pathway by MMA102. 
(HepG2) cell lines were treated with the indicated time points of 3μM of MMA132. β-
Actin was using as loading control. 
 
 
Figure 2.23 Histogram presented the inhibition of EGFRE by MMA102 on HepG2 cell 
line. 
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2.7 Discussion    
Hepatocellular carcinoma is the most prevalent type of cancer worldwide. Recently, 
many evidences have been confirmed that epidermal growth factor receptor (EGFR) is 
overexpressed in HCC. Erlotinib (N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-4-
quinazolinamine) is a standard drug that acts as a potent and reversible inhibitor of EGFR-
TK activity40. In the present study, MMA132 and MMA102 showed an antiproliferative 
effect against HepG2 cell line at a concentration 2 μM and 3 µM, respectively, compared 
to the standard drug Erlotinib, EGFR inhibitor, which is 25 μM after 48 hrs incubation. 
Furthermore, MMA132 showed the greatest activity (2 µM) which is 12 times more than 
Erlotinib 25 µM (Standard drug). 
 The cell cycle provides a critical understanding for coordination between 
proliferation and cell death.  HCC cancer cells line cells undergo replication and division 
by traversing the tightly regulated cell cycle. Growth factors play a critical role in initiating 
signaling events stimulating cell cycle progression, which is crucial for their mitogenic and 
tumorigenic effects. Epidermal growth factor receptor (EGFR) and its ligands are 
frequently upregulated in human cancers. The oncogenic effects of EGFR include initiation 
of DNA synthesis, increase cell growth, invasion, and metastasis48. Specific upregulation 
of EGFR results in cell cycle arrest, apoptosis, or dedifferentiation of cancer cells while 
downregulation of EGFR signaling has therapeutic benefit clinical studies. Therefore, 
better understanding of the mechanisms of regulation and coordination between the cell 
cycle and EGFR inhibitor will lead to the development of novel cancer therapies46. The 
activity of MMA132 and MMA102 against Hepatocellular carcinoma cells were 
demonstrated through cell cycle arrest at G1 phase. 
  To confirm cell cycle arrest at G1 arrested by MMA132 and MMA102, the 
understanding mechanism by which inhibition of EGFR results in apoptosis in HepG2 cells 
is needed. In this work, is needed to link the inhibition of the EGFR to the multiple 
downstream processes, such as DNA fragmentation, and cleavage of PARP by caspase 3. 
These pathways are linking surface receptors to apoptosis39. ELK1 and pELK were 
investigated because they have been shown to be involved in the extracellular-signal-
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regulated kinase (ERK) signaling pathway, inhibition of the ERK signaling pathway in cell 
cycle progression from G1 to S, inhibit phosphorylation of nuclear ERK substrate, such as 
ELK1/pELK46. In addition, EGFR inhibitor such as  Erlotinib which is the stander drug in 
this study was reported as G1 arrested after incubation of the HepG2 cell line with (1-50 
μM) for 24 hrs and led to decrease the proportion of cells in the S phase40 which is similar 
to our results. The proportion of the cells in G2/M phase of the cell cycle during incubation 
with MMA132 and MMA102 remained nearly unaffected. MMA132 arrested the cell cycle 
at G1 phase and inhibited pELK1 after 24 hrs of treatment while MMA102 stopped the 
cycle at G1 phase at concentrations 1.5 and 3 μM. Furthermore, increasing the 
concentration of MMA102 to 6 μM led to arresting the cells at G2 phase. 
 In apoptosis, caspase 3 cleaves 116-KDa, PARP-1 into 85 and 24 KDa PARP-1 
which are required for DNA repair73. The single DNA strand damage and binds to DNA 
leading to the induction of proteins required for base excision repair. Overexpression of 
PARP-1 was correlated to the poor prognosis and survival of HCC74. Inhibition of PARP-
1 is proposed in increasing the sensitivity to DNA-damaging drugs such as Erlotinib75. 
MMA132 induced the cleavage of caspase 9 which activates caspase 3 which leads to 
inhibition of PARP-1. On the other hand, Huether et al, 2003, investigated that Erlotinib 
(EGFR inhibitor) induced activation of caspase 3 after 6 hrs at 50 μm in HepG2 cell line, 
while one of our compounds (MMA132) induced caspase 3 at 2μm concentration74. This 
clearly demonstrated that our lead novel drug candidate produced the apoptotic effect 
through caspase 3 and caspase 9.   
 MMA132, MMA102 and Erlotinib inhibited the invasive and migration potential 
of HepG2 cells at different time points. Inhibition of the hepatocellular carcinoma cells 
migration (HepG2) by MMA132, MMA102 and Erlotinib. The wounds were allowed to 
heal with DMSO treatment control and the migration was inhibited after 48 hrs with 
MMA13276. The data revealed that MMA132 inhibited the cell migration by 100% after 
48 hrs treatment which is better than Erlotinib that inhabited the cell migration by 93% 
after 48 hrs of treatment. 
  EGFR signaling pathway involved in progression and initiation of HCC, in 
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addition, EGFR plays other roles in HCC including RAS, RAF, MEK, and ERK activation 
cascade which leads to induction of transcription of cell proliferation77. To understand the 
mechanism of MMA132 and MMA102 in inhibition of EGFR pathway, western blot 
analysis was conducted. Both MMA132 and MMA102 showed that the phosphorylation 
level of EGFR decreased after 48 hrs. Inhibition of pEGFR lead to downstream signaling 
pathway which lead to tumor proliferation78. Also, the significant increase in EGFR 
expression after 4 hrs of treatment is supports the idea that the receptor’s expression is 
being upregulated in response to the treatment. 
  RAF in EGFR pathway is involved in regulation of many pathological process, in 
addition any overexpression of RAF or activation of phosphorylation RAF is a common 
indicator in proliferation of cancer cells78. Both MMA132 and MMA102 inhibited RAF in 
phosphorylation form, which will cause inhibition of cell proliferation. Moreover, 
activation of MEK and its phosphorylation plays role in the inducing proliferation and drug 
resistance79. MMA132 and MMA102 caused inhibition of pMEK in EGFR pathway 
against HepG2 cell line. Furthermore, ERK/pERK are related to map kinase, which  
regulates cell growth, differentiation, and survival46. CIEA MMA132 and MMA102 
inhibited the pERK level while total ERK remains unchanged in both treatment. In general, 
this clearly demonstrated that MMA132 and MMA102 significantly inhibit EGFR and 
other key proteins that control several cell functions including cell resistance to 
chemotherapy. 
2.8 Summary and conclusions 
 This work highlights the anti-proliferative activity of novel CIEA compounds 
MMA132 and MMA102 on sensitive HCC cells (HepG2) and the mechanism behind this 
effect. Moreover, CIEA increase the apoptotic rate, by inhibition of ERK1/2 signaling 
pathways, and induced caspase 3 and caspase 9 and inhibit PARP-1. CIEA compounds 
MMA132, MMA102, MMA265, MMA240, MMA290 and MMA245 showed 
significantly anti-proliferation activity against HepG2 cell line compared to Erlotinib. In 
addition, MMA132 and MMA102 arrested cells at G1 phase which was confirmed by ERK 
signaling pathway and inhibited pELK1pathway. Also, MMA132 and MMA102 inhibited 
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the whole EGFR pathway as demonstrated through inhibition of the phosphorylation of 
key proteins in EGFR pathway. Moreover, it was investigated that MMA132 induced 
apoptosis significantly as indicated from induction of caspase 3 (67%) and caspase 9 (87%) 
and inhibition of PARP. 
 Briefly, this study established the antiproliferation mechanism of potential drug 
candidate for treatment of hepatocellular carcinoma. 
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3. Chapter Three 
Study the effect of CIEA chemosensitization of HCC/HepG2 resistance cell 
line to Erlotinib  
 
3.1 Introduction 
 
 Cancer is known as a one of serious genetic disorder when cells become abnormal 
and divided very fast. Therefore, if the abnormal cell division is untreated, it will affect the 
other tissues of the body and lead to death1. The major available treatments of cancer are 
chemotherapeutic agents, which can either stop or slow the abnormal fast division of the 
cells. But, cancer cells have the ability to develop resistance to traditional therapies, and 
the increasing spread of these drug resistant cancers require further research and treatment 
development2. The major challenge associated with the available chemotherapeutic agents 
is the drug resistance which involved 30- 80% of cancer patients Therefore, there is an 
urgent need to find a new agent to overcome the resistance to chemotherapeutic agents3. 
For this reason, it becomes an urgent need to find a new agent to overcome the 
chemotherapeutic resistance. 
 
 The phenomenon in which disease become tolerant to pharmaceutical treatments is 
known as drug resistances4. This concept originated when the resistance was observed in 
bacteria against antibiotics, but since then similar mechanisms have been found to occur in 
other diseases, cancer is one of them. Some methods of drug resistance are disease-specific, 
while others, such as drug efflux, which is observed in microbes and human drug-resistant 
cancers, are evolutionarily conserved2. 
 
 Cancer resistance to chemotherapeutic agents is a common reason in patient 
mortality and due to poor/early prognosis of cancer5. At present, the approved drugs for 
advanced HCC is the multi-kinase inhibitor Sorafenib and Erlotinib, which improve overall 
survival of three months in the presence of relevant adverse events6. The high molecular 
heterogeneity of HCC participates in adjustment of the effectiveness of targeted therapies7. 
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 Many studies found that there are two main mechanisms involving in the process 
of resistance in EGFR signaling pathway. Firstly, the genetically secondary EGFR 
mutations could get rid of the inhibition of respective TKIs. Secondly, activation of bypass 
survival tracks via other RTKs or alternative downstream compounds also account for the 
acquired resistance8 .( Figure 3.1) and (Figure 3.2) 9. 
 
 
Figure 3.1 Secondary RTKs-induced EGFR-TKIs resistance. EGFR could trigger 
downstream PI3K/Akt and MAPK signaling axes which in turn stimulate the transcription 
factors to drive the associated genes expression which are related with proliferation, 
angiogenesis, invasion and metastasis. TKIs inhibit EGFR-drive signal transduction by 
interacting with the tyrosine kinase domain of EGFR. Other RTKs are involved in the 
development of TKIs resistance via EGFR-independent way: 1. Amplification of MET 
activates PI3K through transactivating ErbB3; 2. HGF overexpression; 3. ErbB2 
amplification; 4. ErbB3 activation; 5. IGF1R activation by IGF binding or IGFBP 
reduction; 6. AXL activation; 7. FGFR1 activation. 
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Figure 3.2 Alternative downstream compounds-induced EGFR-TKIs resistance. 1. PTEN 
loss: suppressed HGR1 downregulates PTEN expression which in general inhibits the 
PI3K/Akt activation. 2. PIK3CA mutation-derived abnormal activation of PI3K pathway. 
3. BRAF mutation-drive abnormal activation of MAPK signaling axis 
 
3.2 EGFR-independent signaling pathways involved in TKIs resistance 
3.2.1 Secondary RTKs-induced TKIs resistance MET amplification: 
  MET, one of RTKs members family, is increased and correlation the TKIs 
resistance in EGFR-dependent cancers, especially in lung cancer and liver. In a gefitinib-
sensitive lung cancer cells and liver cancer cells, focal amplification of MET was found to 
stimulate ErbB3 phosphorylation which in turn activates downstream PI3K/Akt signaling 
axis recovering the inhibitory effect of gefitinib on EGFR10. At the same time, ErbB3-
specific shRNA inhibited the phosphorylation of Akt and controlled the progression of cell 
cycle in resistant cells. In addition, gefitinib/erlotinib–resistant lung cancer patients, (22%) 
of them were had elevated level of MET and hepatocellular carcinoma patients with classic 
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EGFR-activating mutations were reported to have concomitant MET amplification leading 
to de novo clinical resistance11. Besides lung and liver cancer, MET amplification-derived 
therapeutic resistance was also confirmed in other ErbB-dependent cancers, such as 
colorectal cancer, esophagogastric cancer, and ovarian cancer12’13. Nevertheless, the 
reason why this mechanism has not been reported in other EGFR resistant cells lines and 
cancers is not clear so far especially for HCC patients. Recently , several clinical trials are 
conducted to estimate the activity of combining the MET-targeted drugs (MET-TKIs or 
MET-MAbs) with EGFR TKIs in the treatment of EGFR-mutant tumor with MET-
amplification14 . 
3.2.2 Hepatocyte growth factor (HGF) overexpression: 
  HGF, is the ligand of MET15. The binding between HGF and MET induced various 
biological effects, for instance mitogenic, morphogenic, and antiapoptotic activities 
16.Several studies shown that  the activation of PI3K/Akt pathway behind the TKI 
resistance and contribute to the carcinogenesis, proliferation, and metastasis in EGFR-
mutant lung cancer17. The research implied that HGF could play a crucial role in resistance 
to EGFR-TKI18.  
3.2.3 ErbB2/HER2 amplification: 
   In recent studies, there are many inconsistent views concerning the influence of 
ErbB2 dysregulation on the sensitivity of tumor cells to EGFR-TKIs19,20. Many recent 
studies have confirmed that ErbB2 amplification was recognized as an unacknowledged 
mechanism mediating the acquired TKIs resistance of many types of cancer with the 
absence of the EGFR T790 M mutation21. Moreover, in cases under the treatment with 
Erlotinib, inhibition of ErbB2 with small interfering RNAs (siRNAs) impeded the growth 
of PC-9, HCC827, and H3255 cell lines without EGFR T790 M22. Afatinib, a TKI targeting 
both EGFR and ErbB2, combined with anti-EGFR antibody could remarkably attenuate 
the ErbB2 signaling and in turn resumed the sensitivity of lung cancer and liver cancer to 
TKIs in vitro and in vivo22-23.  
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3.2.4 ErbB3/HER3 activation: 
  Resistances to EGFR or ErbB2-TKIs during the treatment of several malignancies 
were initiated by ErbB324 ,25.ErbB3 can be transactivated and transphosphorylated by 
forming a heterodimers with other ErbB members26. Functionally, ErbB3 plays an essential 
role in  the removal of   the TKIs-inhibited EGFR or ErbB2 to move  and sustain the 
activation of typical PI3K/Akt signaling pathway in vitro and in vivo24. Unlike the EGFR 
and ErbB2 motivating the PI3K during the adaptor proteins, ErbB3 could bind the p85 
subunit of PI3K to activate PI3K directly, involving the priority and spread of the ErbB3-
drived resistance in TKIs-treated tumors27.  
ErbB3 is considered a drug resistance inducer because it is primarily mediated by three 
methods. At first, MET amplification was known to endow ErbB3 signaling with persistent 
activation and contribute to the resistance to gefitinib in lung cancer cell lines 10. Second, 
many researches demonstrated that the ErbB2-ErbB3 heterodimer has an important role in 
the stimulation of downstream oncogenic signaling in ErbB2+ breast cancer cells28. The 
role of ErbB2 to the resistance to gefitinib and erlotinib was undermined significantly by 
TKIs, signaling activities buffering the inhibitory effects of TKIs on ErbB2 were recovered 
through up regulating the production of ErbB3 and weakening the activity of ErbB3 
phosphatase 24. Third, when EebB3 binding with its ligand heregulin (HRG) or neuregulin 
1 (NRG1), it forms a heterodimer with another ErbB receptor. As a result , the ligand-
receptor complex strongly triggered PI3K/Akt axis mediating the resistance to anticancer 
kinase inhibitors in various cancers 29, 30. In result of this mechanism the role of ErbB3 in 
drug resistance mechanisms, is identified as an encouraging approach to resist drug 
resistance31. 
3.2.5 IGF1R activation  
  Activation of IGF1R is another mechanism allowing the gained resistance against 
gefitinib and Erlotinib to EGFR- amplified and EGFR-mutant cancer cell lines31.In 
addition, the signaling mediated by IGF1R participated in the early stage of TKIs-
resistance32.  
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3.2.6 PIK3CA and BRAF mutations: 
 Mutational activation of the downstream signaling components, such as PI3K/Akt 
or MEK/ERK, which was independent on the EGFR was identified as a novel mechanism 
of TKIs resistance33,34. Additionally, BRAF, known as a member of RAS signaling 
pathway genes, BRAF was reported to be involved in promitogenic activity and acquired 
resistance to EGFR TKIs in lung cancer, colorectal cancer and liver cancer through 
activating the MAPK signaling axis35, 36.  
3.3 Mechanisms of resistance to third generation EGFR-TKIs 
  Recently , the third generation EGFR-TKIs, including osimertinib, rociletinib 
(CO-1686), HM61713 (BI 1482694), ASP8273, EGF816, and PF-06747775, are widely 
known  to replace the first generation EGFR- TKIs to overcome the status of drug 
resistance36, 37. Subsequently, patients were also resistant to these TKIs after 10 months of 
treatment, suggesting that additional mechanisms may reduce the efficacy of these 
inhibitors37.  
In conclusion in EGFR inhibitors treatment such as Erlotinib, in approximately 
50% of cases resistance is associated with further mutation of the EGFR, most commonly 
mutation leading to the substitution of methionine for the gatekeeper residue threonine at 
position 790 in the kinase domain (T790M). This mutation in turn increases the affinity of 
the EGFR kinase domain for ATP, which decrease the competitively to the binding of 
EGFR TKIs. Second-generation inhibitors such as afatinib are similarly outcompeted, but 
because they bind irreversibly to EGFR, they nevertheless exhibit some activity against 
EGFR T790M38. Third-generation EGFR TKIs such as rociletinib (CO-1686) and 
osimertinib bind to EFGR T790M with high affinity and have confirmed good activity in 
patients with T790M-mediated resistance to first generation EGFR TKIs39. But until this 
time, targeted anticancer therapies using small molecules provide significant benefits in 
patients with HCC who do not respond well to traditional treatment still challenged because 
of drug resistance cancer40. 
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Erlotinib is consider as the unique drug treatment for advanced (HCC). It appeared 
as a silver lining in combating HCC after decades of search. However, it need many 
improvements before any satisfactory outcomes. One of the explanations is the genetic 
heterogeneity of HCC, which has led to confirming predictive biomarkers for primary 
resistance to erlotinib and sorafenib. This concept is utilized for personalized medicine or 
seeking therapeutic strategies such as combining erlotinib with other anticancer agents. 
Some of the combinations have already shown better effectiveness than Erlotinib or 
sorafenib alone, with good tolerance. In other hand the gained resistance to Erlotinib has 
become an interesting topic for many researchers. Since Erlotinib is a multikinase inhibitor, 
it targets several cellular signaling pathways but simultaneously or sequentially the 
addiction switches and compensatory pathways are activated. Based on the investigated 
mechanisms for acquired resistance to Erlotinib, some other molecular targeted drugs have 
been applied as second line treatment to treat HCC after the failure of sorafenib and 
Erlotinib therapy and more are under evaluation in clinical trials. However, the exact 
mechanisms accounting for Erlotinib resistance remains unclear. Further investigation on 
the crosstalk and relationship of associated pathways will better our understanding of the 
mechanisms and effective strategies for overcoming Erlotinib resistance in HCC41. The 
biggest worry about drug resistance to Erlotinib  is increasing as the OS (overall survival 
)of HCC patients after Erlotinib treatment was only 2-3 months longer than placebo and 
Erlotinib  was shown to result in a limited increase in median time to symptomatic 
progression and a low partial response rate due to drug the mechanisms of Erlotinib  
resistance42. Blocking alternative pathways may provide a promising strategy for 
improving the drug sensitivity and overcoming the resistance to EGFR inhibitors.  
3.4 Mechanism of resistance to Chemotherapeutic agents 
  Different biological reactions represent the  defense drug resistance mechanism 
include: Activation of cellular elimination process, cellular uptake process and metabolic 
reactions to inactivate the drug process inside the cell, all of these processes will cause 
decrease of chemotherapy concentration inside the cell (Figure 1.6)2,43  and (Figure 3.4)2 
.  
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3.4.1 Drug Inactivation 
  Drug activation in vivo includes a series of different proteins interacts with 
substances and these interactions can modify, by part of drug partially degrade, or complex 
the drug with other molecules or proteins, at the end leading to its activation. For most of 
the anticancer drugs metabolic activation is essential to get clinical efficacy. However, 
decrease in drug activation can be a worthy cause of resistance development in cancer 
cells44.  In addition, another source of decrease in the activation of AraC can be down-
regulation or mutation in this pathway, and this can lead to AraC drug resistance. Other 
important examples of drug activation and inactivation include the cytochrome P450 
(CYP) system, glutathione-S-transferase (GST) superfamily, and uridine diphospho-
glucuronosyltransferase (UGT) superfamily45. Because cancer cells can develop resistance 
through decreased drug activation, many anticancer drugs require metabolic activation46.  
  Another cause of drug resistance can be apoptosis-related proteins. For instance, 
apoptosis can be promoted by the tumor suppressor protein p53 (TP53), in response to 
chemotherapy. TP53 is mutated in 50% of cancers47. Otherwise, inactivation of P53 
regulators, such as caspase-9 and its cofactor, apoptotic protease activating factor 1 (Apaf-
1), can also lead to drug resistance48. One more important mechanism of drug activation 
and inactivation is through direct detoxification and mitogen-activated protein kinase 
(MAPK) pathway49.  This is observed in the GST superfamily, which is a group of 
detoxifying enzymes that function to protect cellular macromolecules from electrophilic 
compounds. Increase of GST expression in cancer cells induce detoxification of the 
anticancer drugs, as a result will cause less efficient cytotoxic damage of the cells. This 
increase is also associated with resistance to apoptosis initiated by a variety of stimuli50. 
3.4.2 Alteration of Drug Targets 
       Another method of development of resistance is through alteration of the molecular 
target like mutations or modifications for instance, topoisomerase II is a target for some 
anticancer drugs.  It is an enzyme that prevents DNA from becoming super under-coiled. 
The complex between DNA and topoisomerase II is usually transient, but these drugs 
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stabilize it, leading to DNA damage, inhibition of DNA synthesis, and a halting of mitotic 
processes. Cancer cells can develop resistance to topoisomerase II-inhibiting drugs through 
mutations in the topoisomerase II gene51. One more type of anticancer drug for which 
resistance can develop are the one which targets signaling kinases, such as members of the 
epidermal growth factor receptor (EGFR) family and down-stream signaling partners such 
as Ras, Src, Raf, and MEK. These kinases are constitutively active in certain cancers, and 
this promotes uncontrolled cell growth.  Mutations is the main cause of over-activation of 
these kinases; however, the same effect sometimes results from gene over-expression. In 
addition, the long term use of inhibitors targeting this kinase will result drug resistance52.  
 The increased response rates to EGFR inhibitors in certain liver cancer with EGFR 
tyrosine kinase domain mutations are reported with acquired resistance within one year. 
An EGFR-T790M gatekeeper mutation was reported in half of all cases53.  
3.4.3 Drug Efflux 
  Drug efflux is considered one of the most studied mechanisms of cancer drug 
resistance which involves reducing drug accumulation by enhancing efflux. An important 
transmembrane protein belonging to the ATP-binding cassette (ABC) transporter family 
are responsible for this efflux in addition to transport of a variety of substances across 
cellular membranes. These proteins are present in human cells and all extant phyla. 
Although their structure varies from protein to protein (e.g., there are 49 known members 
of the ABC family in humans), they can be classified on the basis of presence of two 
distinct domains, first is a highly conserved nucleotide binding domain and another is  more 
variable transmembrane domain2. When a given substrate binds to the transmembrane 
domain, ATP hydrolysis occurs at the nucleotide binding site and causes a change in 
conformation that pushes the substrate out of the cell. This mechanism plays important role 
for preventing the accumulation of toxins in cell54. Such ABC transporters are highly 
abundant in liver and intestinal cells, where they protect the cells by pumping all the 
harmful chemicals into the bile duct and intestinal lumen. These transporters also function 
in maintaining blood-brain barrier55’ 2. 
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The constitutive activation of signaling molecules like kinases drives the cell cycle 
out of control and results in cancer. Conversely, over-expression of proteins involved in 
the MAPK pathway, such HRas, c-Raf, MEK1/2, ERK1/2, which act downstream of 
receptor tyrosine kinases, increases the expression of Pgp. While inhibitors of the 
extracellular signal-regulated kinases (ERK) pathway down-regulate Pgp expression, 
growth factors like EGF and FGF increase it. Interestingly, inhibition of HSP90, a 
chaperone protein that stabilizes many signaling proteins, also down-regulates Pgp2. 
3.4.4 DNA Damage Repair 
 Some group of chemotherapy drugs target DNA and directly or indirectly damage 
DNA of cancerous cells. In this type of drugs, anticancer drug resistance can develop, in 
which cancer cells repair the damaged DNA by DNA damage response (DDR) mechanism 
which can reverse the drug-induced damage. For example, platinum-containing 
chemotherapy drugs such as Cisplatin cause harmful DNA crosslinks, which can lead to 
apoptosis. However, resistance to platinum-based drugs often arises due to nucleotide 
excision repair and homologous recombination, the primary DNA repair mechanisms 
involved in reversing platinum damage. Therefore, for the DNA-damaging cytotoxic drugs 
to be effective there should be the failure of the cancer cell’s DDR mechanisms. Inhibition 
of repair pathways used in conjunction with DNA damaging chemotherapy could sensitize 
cancer cells and therefore increase efficacy of the therapy56. 
3.4.5 Cell Death Inhibition 
        Cell death by apoptosis and autophagy are two important regulatory events. Although 
these processes are antagonistic to one another, they both have a role to cell death. 
Apoptosis has two established pathways: an intrinsic pathway mediated by the 
mitochondria that involves B-cell lymphoma 2 (BCL-2) family proteins, caspase-9 and 
Akt, and an extrinsic pathway that involves death receptors on the cell surface. The intrinsic 
and extrinsic pathways merge through the activation of down-stream caspase-3, which 
ultimately causes apoptosis2. In several types of cancers, BCL-2 family proteins, Akt, and 
other antiapoptotic proteins are highly expressed and down-stream transcription 
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modulators like NF-κB and STAT are highly active, making these good targets for drug 
development. Because of activation of c-Jun N-terminal kinases (JNK) many cancer drugs 
also induce apoptosis, which is downstream of the MAPK pathway57. All of these 
mechanisms are contribute in drug resistant, can be effectively treated by using one drug 
that makes the cells susceptible to death through the altered expression or regulation of cell 
death pathway members in combination with another cytotoxic drug that kills the cells in 
their vulnerable states, as a result the apoptosis and autophagy in cancer have a role in drug 
resistance have which makes it especially important in the field of drug-resistant cancers58. 
3.4.6 Epithelial-Mesenchymal Transition and Metastasis 
  The epithelial to mesenchymal transition (EMT) is one of the solid tumor become 
metastasis mechanism. Metastasis itself is a complex phenomenon that includes changes 
in a cancer cell and the stromal cells that change its environment( cell migration) (Figure 
3.3)59. It also includes angiogenesis, which is the process responsible to form a new blood 
vessel around metastatic tumors. The mechanism of EMT, starts when the cells within a 
tumor reduce the expression of cell adhesion receptors, including integrins and cadherins, 
which help in cell-cell attachment, and increase the expression of cell adhesion receptors 
that induce cell motility. Cell motility is also based on cytokines and chemokines, which 
may be released by cells in the microenvironment of tumors or by the tumors themselves. 
Additionally, higher expression of metalloproteases on the surface of tumors it is contribute 
in clear the road for the cells to move outward, promoting metastasis. The role of EMT in 
cancer drug resistance is an emerging area of research60. 
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Figure 3.3 Multistep metastatic process of cancer cells. The molecular basis of tumor 
progression depends on local invasion, intravasation, survival in the circulation, 
extravasation and colonization. 
 
3.5 Role of Epigenetics in Cancer Drug Resistance 
   Epigenetic modifications are an important set of mechanisms that cause resistance 
to cancer treatment and that have not been readily discussed and can also influence 
carcinogenesis. Epigenetic classified to two types changes are DNA methylation and 
histone modification via acetylation or methylation. DNA methylation consists of methyl 
groups binding to cytosines at CG-dinucleotides within regions known as CpG islands, 
primarily found in upstream gene promoter regions. But, methylation can occur at other 
loci throughout the genome. on the contrary, histone modifications alter chromatin 
conformation. For example, histone acetylation opens the chromatin, while deacetylation 
closes it. These mechanisms ultimately regulate the expression of genes throughout the 
chromosome, and in cancer, this normal regulation is broken. For example, tumor 
suppressor genes are often silenced via hypermethylation, and oncogenes are over-
expressed via hypomethylation. However, epigenetic mechanisms are usually reversible, 
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and researchers may be able to take advantage of this opportunity to develop treatments 
that can counteract drug resistant cancers2,61.          
 
Figure 3.4 Depiction of the primary mechanisms that enable cancer cells to become drug 
resistant. 
 
3.6 Properties of resistant cells generated from HCC cell lines treated with EGFR 
inhibitors (Erlotinib) 
  Epidermal growth factor receptor (EGFR) signaling plays an important role in HCC 
and therapeutics targeted against EGFR have been effective in treating a subset of patients 
bearing somatic EFGR mutations. Because, the cancer eventually progresses during 
treatment with EGFR inhibitors, even in the patients who respond to these drugs initially. 
Recently, many studies have identified that the conquest of resistance in approximately 
50% of cases is due to generation of a secondary mutation (T790M) in the EGFR kinase 
domain. In about 20% of the cases, resistance is associated with the amplification of MET 
kinase. In the remaining 30-40% of the cases, the mechanism underpinning the therapeutic 
resistance is unknown61.  
In this study We want to determine whether CIEA compounds have Anti-
proliferation effect against Erlotinib Resistant HepG2 cell line and study the mechanism of 
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theses CIEA compounds on EGFR signaling pathway on resistance to Erlotinib by 
establishing Erlotinib-resistant cell sub- line from HepG2 cells.  
    Aim of the study: There for understanding the mechanism and antiproliferative 
activity of CIEA against HEpG2-R for studying the effect of CIEA chemosensitization of 
HCC/HepG2 resistance cell line to chemotherapy drugs (Erlotinib)  
 
3.7 Materials and Methods 
 
3.7.1 Development of HepG2 resistant cell line 
 Human sensitive liver cancer cell line HepG2 (ATCC, ManassaVA) was used in 
this study to develop the resistance. The cells were maintained in EMEM (Eagle's 
Minimum Essential Medium) (ATCC, ManassaVA)) supplemented with 10% FBS 
(Atlanta biologicals) and 1% penicillin (100 IU/mL)/streptomycin (100 μg/mL) (Corning) 
at 37°C, 5% CO2. During culture, the medium was changed every other day. The cells 
were passaged every 5-6 days using Trypsin-EDTA (0.25% trypsin, 1 mM EDTA) 
(Hyclone™ L aboratories, Inc). The protocol to develop resistance cell line against 
Erlotinib(Selleckchem) was presented by Ghosh et al., 201262, starting with an Erlotinib 
(Selleckchem) concentration of 2.5 μM, the exposure dose was doubled every15 days until 
a final concentration of 25 μM was achieved , which is the IC50 of Erlotinib that has been 
reported against HepG2 cell line . The cells were maintained in continuous culture at 25 
μM Erlotinib for 30 days. Then the resistance phenotype of the cells was characterized by 
a cell proliferation assay. Cell viability was then measured following exposure to varying 
concentrations of Erlotinib. 
3.7.2 Cytotoxicity assay 
  The resistant hepatoma cells (HepG2-R) were seeded in 96-well plate as 5*104 
cells/mL (100 μL/well). A serial dilution of MMA132 and MMA102 compounds were 
added after overnight incubation of the cells at 37°C and 5% CO2. DMSO (Acros 
Organics) was used as a control (0.1 %). The cells were incubated with the compounds for 
48 hrs. After that 15 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
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(MTT) (Sigma Aldrich) (5 mg/mL PBS) were added to each well and the plate was 
incubated for another 4 hrs. The formazan crystals were solubilized by 100 μL acidified 
SDS solution (10% SDS/0.01 N HCl) (Fisher BioReagents). The absorbance was measured 
after 14 hrs of incubation at 37°C and 5% CO2 at 570 nm by Hidex Sense Microplate 
readers63. 
3.7.3 Cell Cycle Analysis 
 According manufacturer protocol64, HepG2-R cells were seeded into six-well plates 
at a concentration of 300,000 cells/ well and allowed to attach in culture overnight, then 
treated with IC50 values of compounds (MMA132 13 μM and MMA102 20 μM) for 48 h. 
Afterwards, cells were washed with PBS and harvested. Cell cycle analysis was 
investigated in accordance with the manufacturers protocol with slight modification. 
Briefly, Vybrant® DyeCycle™ Green Stain (Thermo Fisher Scientific) was added to 1 ml 
of cell suspension at a final concentration of 0.0625 μM. After 45 minutes of incubation at 
37˚C, the samples were analyzed by flow cytometry and compared to DMSO-treated cells. 
All these experiments were performed on BD Accuri™ C6 flow cytometer (BD 
Biosciences, San Jose, CA, USA) using BD Accuri™ C6 software, version 1.0. 
3.7.4 Cell Migration (Wound Healing Assay)    
  The HepG2-R cells were seeded into 24-well tissue culture plate at a density that 
after 24 h of growth, they should reach ~70-80% confluence as a monolayer. By a new 1 
ml pipette tip the well was gently and slowly scratched across the center. While scratching 
across the surface of the well, the long-axial of the tip was always perpendicular to the 
bottom of the well. The resulting gap distance therefore equals to the outer diameter of the 
end of the tip. After scratching, gently the wells were washed twice with cold 1X PBS to 
remove the detached cells.  The cells were either incubated with of MMA132 (13μM) and 
MMA102 (20μM) for different time points (zero time, 1hr, 24hrs, and 48 hrs). The photos 
for the monolayer and cell movement were taken by a microscope at different time points. 
The gap distance can be quantitatively evaluated using ImageJ software65 
94 
 
 
 
3.7.5 Western blot analysis 
 The HepG2-R protein lysate and western blot method was prepared and done 
according to El-senduny et al66.    HepG2-R cells were treated with 13 µM and 20 µM of 
MMA132 and MMA102 respectively, and incubated for 1, 24, 48 hrs. Briefly, cells were 
lysed with 1X RIPA buffer(Thermoscientific™Pierce™) containing protease and 
phosphatase inhibitors. The BCA protein assay was used to quantify total protein 
concentration. An amount of 20 µg was loaded onto 10% SDSPAGE [ERK, PERK (Cell 
Signaling Technology), MEK, pMEK (ThermoFisher Scientific), RAF, pRAF (Cell 
Signaling Technology)] and 8% SDSPAGE [EGFR, pEGFR (Cell Signaling Technology)] 
per well. The protein was transferred onto 0.45micron nitrocellulose membrane and 
blocked with 5% BSA (Sigma Aldrich), and subsequently incubated with ERK, pERK, 
MEK, pMEK, RAF, pRAF and EGFR, pEGFR primary antibodies overnight at 4°C. The 
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The 
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive 
control. 
3.8 Results and Discussion: 
3.8.1 Characterization of an Erlotinib resistant cell line 
  Human sensitive liver cancer cell line HepG2 from ATCC (Manassas, VA), was 
used in this study to develop the resistance properties. The cells were maintained in EMEM 
(Eagle's Minimum Essential Medium) supplemented with 10% FBS and glutamine. During 
culture, the medium was changed every other day. The cells were passaged every 5-6 days 
using Trypsin-EDTA (0.25% trypsin, 1 mM EDTA). The protocol to develop resistance 
cell line against Erlotinib was presented by Ghosh et al., 201262, starting with an Erlotinib 
(Selleckchem) concentration of 2.5 μM, the exposure dose was doubled every 15 days until 
a final concentration of 25 μM was achieved, which is the IC50 of Erlotinib that has been 
reported against HepG2 cell line . The cells were maintained in continuous culture at 25 
μM Erlotinib for 30 days. Then the resistance phenotype of the cells was characterized by 
a cell proliferation assay. Cell viability was then measured following exposure to varying 
concentrations of Erlotinib.  
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 After erlotinib resistant HepG2 cell line (HepG2-R) was generated by progressively 
exposing the cells to gradually increased concentrations of Erlotinib according to the 
protocol presented, the cells were passed every 5-6 days and developed resistant HepG2 
cell line when the exposure dose was doubled every 15 days. Cell treated with 25 uM 
showed a full resistant properties to chemotherapy maintained for 30 days in the presence 
of erlotinib. Resistant cells to 25 µM erlotinib concentration were used for studying the 
mechanism of resistant cells to chemotherapy. 
3.8.2 Study Anti-proliferation Activity of Erlotinib and CIEA Compounds (MMA132 
and MMA102) to Resistance HepG2 Cell line  
       To confirm the resistant, phenotype was characterized by determining the ant-
proliferation activity of Erlotinib resistant HepG2 cancer cells, the cells were treated for 48 
hrs and its viability was determined by MTT assay. Figure 2-5 shows the cytotoxic effects 
of the Erlotinib, MMA132, and MMA102 on resistant cell lines. For the Erlotinib the 
resistant cells were characterized by quantifying cell viability at different concentrations 
of Erlotinib. Erlotinib showed no cytotoxic activity against HEpG2-R after 48 hrs 
incubation with 25 μM, which confirms the resistance properties of HepG2 to Erlotinib. 
The IC50 values of MMA132 and MMA102, as the most active compounds against 
sensitive HepG2 cell line, were 13 μM and 20 μM respectively against HepG2-R compared 
to erlotinib as a standard drug for hepatocellular carcinoma that has no cytotoxic activity 
on hepatoma resistant cell line. In addition, both CIEA compound MMA132 and MMA102 
have high antiproliferative activity on resistance cells more than Erlotinib on sensitive cells 
as candidate compounds. The sensitization activity of each CIEA MMA132 and MMA102 
was tested by incubating the cells for 48 hrs (Figure 3.5).  
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Figure 3.5 IC50 curves for MMA132, MMA102 compounds and Erlotinib on HepG2-R 
cell line compared to DMSO control. 
 
3.8.3 Inhibition of Cell Migration (Wound Healing Assay) by MMA132 and MMA102 
against HepG2-R 
 To investigate whether MMA132 and MMA102 have a role in cell migration and 
in vitro invasion on HepG2-R cell line and to determine the affected migration and in vitro 
invasion after development of resistant HepG2 cell line, we measured the cell migration in 
HepG2-R cells treated with 13 μM of MMA132 and 20 μM of MMA102. In these 
experiments, cells are grown to confluency and an incision was made in the center of the 
wells. Cells were initially seeded in 6-well culture plates with an artificial ‘‘wound’’ 
carefully created at 0 h, using a P-200 pipette tip to scratch on the confluent cell. The 
relative movement of cells to cover the ‘‘wound’’ was measured after 48 hours.  Monolayer 
microphotographs were taken at 0 and 48 h. As shown in Figure 3.6, MMA132 inhibited 
cell migration and in vitro invasion of HepG2-R cells compared with controls. In addition, 
MMA102 still has activity to inhibit cell migration against HepG2-R cell line but less than 
the MMA102 activity against sensitive HepG2 cell line. 
97 
 
 
 
 
Figure 3.6 Wound-healing assay. HepG2-R cells were grown to confluency and a linear 
‘‘wound’’ was made with a pipette tip. After 48 hours of incubation in the presence of 
DMSO (control) or with 13 μM of MMA132 and 20 μM of MMA102 a microscopic 
photograph was taken at zero time and after 48 hrs. 
 
3.8.4 Effects on cell cycle distribution against HepG2-R cell line  
 In order to better understand the mechanism of CIEA against resistant HepG2 cell 
line, we analyzed the distribution of cells in different phases of the cell cycle by flow 
cytometry following treatment of cells with different compounds (with 13 μM of 
MMA132, 20 μM of MMA102 and DMSO as a control). We found that the resistant cells 
started to behave differently from sensitive cells in cell cycle arrest with different treatment 
caused cell accumulation in the G2 phase (Figure 3.7). For resistant cells, treatment of 
HepG2-R cells with 13 μM of MMA132 led to arrest 44.8% of cells in the G2 phase while 
treating with 20 μM of MMA102 led to arrest the cells in the G2 phase by 41.7% compared 
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to 38.0% in control. In general, these results indicated that cell cycle progression was 
significantly blocked in the G2 phase when resistant cells were treated with MMA132 and 
MMA102 respectively comparing to DMSO control. 
 
 
Figure 3.7 Flow cytometric analysis of the cell cycle of HepG2 cancer cells. Cells were 
treated with different concentration of MMA102 (1.5 µM, 3 µM and 6 µM) respectively 
compared to DMSO control. 
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Figure 3.8 Histogram showing the percentage of cells in the G2 phase. 
 
Table 3.1 cell cycle phases on HepG2 and HepG2-R with different treatment of 
MMA132 and MMA102 
Cell Cycle Phases HepG2 HepG2-R 
MMA132 
G1 
S 
G2 
 
41.0% 
37.4% 
21.0% 
 
 
26.1% 
11.2% 
44.8% 
MMA102 
G1 
S 
G2 
 
47.0% 
22.0% 
31.0% 
 
30.0% 
9.7% 
41.7% 
 
3.8.5 MMA132 and MMA102 treatment against HepG2-R lead to an alteration in the 
EGFR signaling pathways  
 The level of EGFR proteins pathway was detected after 13 μM of MMA132 and 20 
μM of MMA102 drug treatment. MMA132 showed an effect on the whole EGFR pathway, 
and this effect of inhibition started after 24 hrs of treatment for the most proteins pathway. 
It was found that the phosphorylation level of EGFR, RAF and MEK were decreased in 
the resistant cells (Figure 3.9), which is similar to the inhibition caused by MMA132 in 
sensitive HepG2cell line (Figure 2.20). In contrast to, the phosphorylation level of ERK 
in resistant cells didn’t show the same inhibition of MMA132 in sensitive HepG2 cell line. 
In addition, MMA132 showed a unique effect in EGFR pathway by reduced total EGFR. 
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Also, MMA102 (Figure 3.11), leads to a decrease in p-ERK and p-MEK after 24 hrs 
treatment in HepG2-R cell line (Figure 3.11).  
 The Raf/MEK/ERK pathway has different effects on growth, prevention of 
apoptosis, cell cycle arrest and induction of drug resistance in cells of hepatocellular 
carcinoma. The data revealed that MMA132 and MMA102 inhibited the p-RAF which is 
considered as an indicator for inhibition of cell proliferation. Because p-RAF regulates 
gene expression, it prevents apoptosis and induces cell proliferation67.  
 MEK/ERK induced proliferation, drug resistance. MEK also influences 
chemotherapeutic drug resistance. Moreover, it has been observed that overexpression of 
MEK is associated with a worse prognosis of drug resistance. Both MMA132 and 
MMA102 decrease the phosphorylation level of MEK after 24 hrs. also, MMA102 
inhibited the p-MEK by 100% after 48, which makes our CIEA as a promising drug 
candidate for drug resistance. In addition, ERK in EGFR signaling pathway in caner plays 
a vital role in inhibition of apoptosis and increases cell growth. ERK also has an essential 
role in regulation of the cell cycle arrest in cancer cell and induction of drug resistance 
through inhibition of apoptosis67. From Figure 3.9 and figure 3.11, the data presented that 
MMA132 and MMA102 inhibited the phosphorylation form of ERK which means 
decreasing the cancer cell growth and inhibiting the drug resistance.  
 Moreover, targeted inhibition of the central components of this pathway appears to 
be an excellent choice for future therapeutic approaches. It has been observed that 
overexpression of both the Raf/MEK/ERK in EGFR pathway is associated Drug 
resistance74. 
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Figure 3.9 Changes in the expression level of EGFR signaling proteins by MMA132. 
Western blot analyses of EGFR and downstream signaling pathway activation. The 
HepG2-R cells line were treated with the correspondent IC50 of MMA132 (13 µm) for 1, 
24, 48 hrs, β-Actin used as a loading control. Each experiment was performed in triplicate. 
The values above indicate relative expression level compared with control. 
   
 
Figure 3.10 Histogram showing the inhibition of EGFR signaling pathway by MMA132 
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Figure 3.11 Changes in the expression level of EGFR signaling proteins by MMA102. The 
HepG2-R cells line were treated with the correspondent IC50 of MMA102 (20 µm) for 1, 
24, 48 hrs, β-Actin used as a loading control. Each experiment was performed in triplicate. 
The values above indicate relative expression level compared with control 
 
Figure 3.12 Histogram showing the inhibition of EGFR signaling pathway by MMA102 
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3.9 Discussion            
  Hepatocellular carcinoma (HCC) is the most common histological form of primary 
liver cancer, the tumor cells retain the features of hepatocytic differentiation. Erlotinib is 
the most effective chemotherapy drugs for HCC treatment. The low levels of survival in 
HCC patients is related to resistance of the HCC cell to this drug. This is a big challenge 
in HCC treatment in this time68. In the present study, Erlotinib alone showed an inhibitory 
effect on sensitive HepG2 cell. Moreover, in this study, development of resistant HepG2 
cell line to Erlotinib (standard drug), cells were characterized by quantifying cell viability 
at different concentrations of Erlotinib. Erlotinib showed no cytotoxic activity against 
HEpG2-R after 48 hrs incubation with 25 μM, which confirms the resistance properties of 
HepG2 to Erlotinib and leads to investigate the cytotoxicity effect of CIEA compounds on 
resistant HepG2 cells line. The novel compounds MMA132 and MMA102 were effective 
on resistant cells more than Erlotinib itself in sensitive cells. Also, MMA132 and MMA102 
showed antiproliferative activity against HepG2-R cells with 13 μM and 20 μM, 
respectively, after 48 hrs of incubation. This clearly demonstrated that MMA132 and 
MMA102 significantly has cytotoxic activity to inhibit resistance to Erlotinib. 
  MMA132 and MMA102 activity against HCC were through cell cycle arrest at 
G2/M phase, which is different from the effect of both MMA132 and MMMA102 on 
sensitive HepG2 cells line which was G1 arrest. For resistant cells, treatment of HepG2-R 
cells with 13 μM of MMA132 led to arrest 38.0% of the cells in control at G2 phase to 
increase 44.8% of cells that are treated with MMA132 in the G2 phase, and to 41.7% with 
cells treated with MMA102 after 24 hrs of incubation with 13 μM and 20 μM of MMA132 
and MMA102, respectively. In contrast, HepG2 sensitive cells were completely stopped at 
G1 phase at different concentration of MMA132 and MMA102. These results indicate that 
cell cycle progression was significantly blocked in the G2 phase when resistant cells were 
treated with MMA132 and MMA102, respectively, comparing to DMSO control. Zhai at 
al., in a different study have found that in HepG2 resistant to adriamycin (ADM), the 
number of cells in S-phase and G1 was significantly decreased (5. 6%) in HepG2/Adm 
while those G2-phase increased (24%)69.Change the behavior of resistance cells in cycle 
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arrest to stop the cell cycle at G2 phase confirmed the resistance properties of cells to 
Erlotinib. 
 Inhibition the cell migration of resistant hepatocellular carcinoma cells (HepG2-R) 
by MMA132 and MMA102, the wounds were allowed to heal with DMSO treatment 
control and the migration was inhibited after 48 hrs with both MMA13 and MMA1022. 
Furthermore, we measured the cell migration in HepG2-R cells treated with 13 μM of 
MMA132 and 20 μM of MMA102. It was found that MMA132 inhibited the cell migration 
and in vitro invasion of HepG2-R cells compared with controls. In addition, MMA102 still 
has activity to inhibit cell migration against HepG2-R cell line but less than sensitive one. 
Generally, in Comparison with Erlotinib in sensitive cell, MMA132 treatment with 
resistance HepG2 cell line has activity to inhibit the cell migration after 48 hrs more than 
Erlotinib in sensitive cell.  
 The effect of MMA132 and MMA102 on the EGFR pathway against HepG2-R was 
different form sensitive cells.  MMA 132 doesn’t have a clear activity in inhibition of the 
phosphorylation level of ERK, which clearly demonstrated the behavior of cell cycle arrest 
at G2 phase because the role of ERK pathway to regulate G1 phase. In contrast MMA132 
has a huge inhibition on total EGFR and p-EGFR. It also inhibited the phosphorylation 
level of MEK and RAF while MMA102 decreased the pERK1/2 and PMEK levels in the 
resistant HCC cell line. Hence, these results show the effect of CIEA on the EGFR 
signaling pathway in HepG2-R. 
 MEK/ERK induced proliferation, drug resistance. MEK also influences 
chemotherapeutic drug resistance67. Moreover, it has been observed that overexpression of 
MEK is associated with a worse prognosis of drug resistance. Both MMA132 and 
MMA102 decrease the phosphorylation level of MEK after 24 hrs, and MMA102 inhibited 
the p-MEK by 100% after 48, which make our CIEA a promising candidate drug for drug 
resistance. In addition, ERK in EGFR signaling pathway in caner plays role in inhibit the 
apoptosis and increases cell growth. The data presented that MMA132 and MMA102 
inhibited the phosphorylation form of ERK which means decreasing the cancer cell growth 
and inhibiting the drug resistance. 
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 In conclusion, this study confirmed the antiproliferative activity of MMA132 and 
MMA102 in drug resistance and demonstrated the mechanism of potential drug candidate 
for treatment and solve the drug resistant in hepatocellular carcinoma. 
3.10 Summary and conclusions  
 Our study indicates that prolonged exposure of the Hepatocellular carcinoma cell 
line HepG2 to erlotinib selects for a subpopulation of erlotinib resistant cells which are 
enriched in stem cell markers and possess stem cell properties in vitro. Furthermore, these 
cells were found to be less sensitive to erlotinib treatment as determined by cell viability. 
Resistant HepG2 showed resistant properties to erlotinib after 3 months of maintenance in 
Erlotinib. HepG2 cells also showed decrease in the number of cells in G1 phase from 38% 
in control to 26.1% in MMA132 treatment and 30.1 in MMA102 treatment which is 
different from the sensitive HepG2 cell line. Our studies indicated that both MMA132 and 
MMA102 inhibit the HepG2-R cell migration after 48 hrs of incubation. 
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4. Chapter Four 
 Study the role of multidrug resistance associated proteins (MRPs) against sensitive 
HEPG2 and resistant HEPG2R cell lines 
 
4.1  Introduction 
   Cancer cells have ability to develop resistance to structurally and mechanistically 
unrelated drugs over a period of time1.  Chemotherapy is one of the major 
treatment modalities available for cancer patients. Unfortunately,  during this course of 
treatment, cancer cells start develop  resistance to functionally and structurally 
different  anticancer drugs by either acquired (due to host factors)  or intrinsic (due to 
genetic or epigenetic) mechanisms2 . Later on, when the cells selected for resistance to a 
single cytotoxic drug, tumor cells may become resistant against an entire range of drugs 
with different chemical structures and cellular targets, a phenomenon called multidrug 
resistance (MDR)3.  
 Many studies about MDR suggested that drug transport is a carefully controlled 
process, and this process was later found to be regulated by members of the ATP binding 
cassette (ABC) transporter family of proteins. P-glycoprotein (P-gp)/ABCB1 was the 
first  identified ABC transporter4 .   In addition, this protein has been confirmed to play a 
role in many cellular functions. Recently, has been identified 49  different ABC 
transporters  in  humans, though there are more in bacteria and  parasites5 .  
 ABC transporters have been identified into seven subfamilies, ABCA to G, 
depends on sequence similarities. Of them the major ABC transporters  involved in MDR 
development are ABC subfamily B  member 1 [(ABCB1/P-glycoprotein (P-gp)], 
ABC  subfamily G member 2 [ABCG2, also known as breast  cancer resistance protein 
(BCRP)/mitoxantrone  resistance protein (MXR)/placenta-specific ABC protein  (ABCP)], 
and ABC subfamily C member 1  (ABCC1/MRP1)6 . 
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  The ABC transporter superfamily includes membrane proteins that include a wide 
variety of substrates across cellular membranes. An increasing number of 
chemotherapeutic drugs transported by ABC transporters have been recognized since the 
discovery of P-gp 1 (Figure 4.1)7.   
 
Figure 4.1 ABC transporters proteins in multidrug resistance that mediate 
chemotherapeutic drug resistance.  
 
  The MRP subfamily, the C subset of the ABC transporter superfamily, is classified 
to thirteen  members, and nine of these are primarily involved in  MDR (Table4.1)8.These 
nine MRPs have  been established as ATP dependent efflux transporters based on 
functional characterization,  localization, and cloning studies for endogenous substances 
and xenobiotics. The other three members of the MRP subfamily, namely  ABCC7/cystic 
fibrosis transmembrane conductance  regulator (CFTR), ABCC8/sulfonylurea receptor 
SUR1), and ABCC9/SUR2, are not involved in  conferring MDR2. The role of ABCC7 is 
to regulate chloride channel,  whereas ABCC8 and ABCC9 are intracellular ATP  sensors 
and regulate the specific K + channel permeability9 . 
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Table 4.1 Summary of MRP members involved in MDR 
MRP 
Member 
Alternative name 
Amino acid 
identity with 
MRP (%) 
Tissue 
distribution 
MRP1 ABCC1 100 Ubiquitous 
MRP2 
ABCC2, cMOAT, 
cMRP 
50 Liver, kidney, gut 
MRP3 
ABCC3, MOAT-D, 
cMOAT-2 
58 
Liver, pancreas, 
kidney 
MRP4 ABCC4, MOAT-B 41 
Prostate, lung, 
muscles 
MRP5 
ABCC5, MOAT-C, 
Pabcc11 
38 Ubiquitous 
 The nine main MRPs can be classified into two groups. One has a typical ABC 
transporter structure and is composed of two membranes spanning domains (MSD) with 
nucleotide binding domains (NBD1 and NBD2) in between (Figure 1.7).  These can be 
referred to as a “short MRPs” and include MRP4, MRP5, MRP8, and MRP9 (ABCC4, 5, 
11 and 13, respectively). The other group, which include MRP1, 2, 3, 6 and 7 (ABCC1, 2, 
3, 6 and 7, respectively), have an additional MSD (MSD0) and are referred as “long MRP10. 
  Many studies have been confirmed that overexpression of MRP1 is associated with 
an increased transport rate of a range of substrates that are conjugated to glutathione (GSH), 
glucuronide, or sulfate11,12. This transporter mechanisms are known as glutathione 
conjugate (GS-X) pumps, or multi-specific organic anion transporters3. Besides organic 
anions MRP1 can also transport neutral and basic cytotoxic drugs not known to be 
conjugated to GSH or other negatively charged compounds13. Notwithstanding, MRP1 
requires the presence of intracellular glutathione for the transport of these drugs. It is 
credible that MRP2 could play a role in drug resistance, just as MRP1 does. Studies with 
mutant rats (TR– /GY or EHBR) that lack the MRP2 protein in the hepatocanalicular 
membrane and transfection studies with MRP2 cDNA showed that the substrate specificity 
of MRP2 is very similar to that of MRP114, and suggested that MRP2 is able to transport 
several anticancer drugs15. 
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4.2  ABC transporters as multidrug resistance mechanisms 
 The adenosine triphosphate (ATP)-binding cassette (ABC) transporters are found 
in all organisms. These transporters proteins have been reported to have a role in multidrug 
resistance in cancer. ABC transporters were so named because of the presence of a 
conserved ATP-binding domain which provides the energy required for a conformational 
change16.  
Figure 4.2 explains the general drug efflux mechanism of MDR transporters in 
cancer cells. First, the anticancer drug molecules penetrate the plasma membrane through 
passive diffusion (Figure 5.2a). Next the drug molecules bind to the TMDs, the NBDs are 
activated. Subsequently, ATP hydrolysis causes a major conformational change of the 
MDR transporter, which ultimately transports the drug molecules into the extracellular 
space (Figure 5.2b). This active transport of chemotherapeutic drugs out of the cell, 
severely reduces the amount of drug molecules accumulated in the cancer cells and the 
effectiveness of chemotherapy17. 
 The protection of normal tissues such as kidney, liver, pancreas, and the 
endothelium of blood vessels of the brain is the vital role of ABC transporters. Among 
these transporters, the ones that are most likely to mediate chemotherapeutic drug 
resistance are permeability-glycoprotein (P-gp), multidrug resistance-associated protein-1 
(MRP1) and breast cancer resistance protein (BCRP) (Figure 1.5)18. 
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Figure 4.2 S diagram of the general drug efflux mechanism of an MDR transporter in the 
plasma membrane of a cancer cell. (a) Drug molecule enters the plasma membrane through 
passive diffusion. (b) The efflux pump, energized by the hydrolysis of a bound ATP 
molecule, ejects the drug molecules out of the cell. Redrawn based on the schematic 
diagram published in Cancer Control. 
 
4.3  MRP2/ABCC2 
    MRP2 is the second member of the MRP subfamily of ABC transporter. The first 
time MRP2 was cloned from rat hepatocyte and was named as a hepatocellular canalicular 
multiple organic anion transporter (cMOAT)19. In addition, MRP2 shares 49% amino acid 
identity with MRP1 but it has a different expression pattern. While MRP1 is widely 
expressed in  many tissues, MRP2 is mainly expressed in the apical  (canalicular) 
hepatocyte plasma membrane, small  intestine, and renal proximal tubules (Table 
1)2.  mRNA is present in the peripheral nerves, gallbladder, placental trophoblasts, and 
CD4 + lymphocyte2, 20,21. 
Because of the similarity between MRP2 and MARP1, it was believed to 
confer resistance to similar anticancer drugs as well. This hypothesis was created based on 
an experiment in which an antisense RNA construct was introduced into human 
hepatocellular carcinoma HepG2 cells, causing in increased sensitivity to several 
anticancer drugs such as cisplatin, vinblastine, sorafenib, doxorubicin, and Erlotinib19. 
MRP2 have been demonstrated TO transport vinblastine in polarized Madin Darby 
canine kidney epithelial (MDCK) cells, proposing a potential role for MRP2 in vresistance. 
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In addition, transfected cells also conferred resistance to cisplatin,  etoposide, doxorubicin, 
and epirubicin .This phenomenon is convincible to suggestion  a potential role for MRP2 
in  drug  resistance such as Erlotinib against HepG2 resistance cell line15. 
 The expression of MRP2  has been reported in several  human tumor cell lines of 
lung, gastric, renal, and  colorectal cancers22  . Moreover, few cisplatin and doxorubicin 
resistant cell lines have shown overexpression of MRP223. Recently, Korita24, suggest that 
efficacy of cisplatin-based chemotherapy in patients with hepatocellular 
carcinoma depends upon MRP2 expression level24.  
4.4  Physiological and pharmacological function of MRP2 
  Many studies have been confirmed that MRP2 is important from a pharmacological 
function. Firstly, MRP2 has essential role in the intracellularly formed glucuronide and 
GSH-conjugates of clinically important drugs25. Secondly, MRP2 is inhibition of the ATP-
dependent excretion of bile also involved in the biliary excretion of non-conjugated anionic 
drug26. For example, the efficient biliary excretion of pravastatin, an HMG-CoA reductase 
inhibitor, this process is mediated by MRP227.  After exhibiting its pharmacological action 
in the liver, pravastatin is then excreted into the bile via MRP2 without metabolic 
conversion28. Thus, efficient biliary excretion by MRP2 plays an important role in the 
entero-hepatic circulation, which is responsible for maintaining significant plasma 
concentrations of drugs. The mechanism for the substrate recognition by MRP2 still 
remains to be clarified, although Han et al.29 suggested the importance of the non-polar 
surface area in determining the affinity using a series of methotrexate analogues29. 
 Many tumor tissues have been  reported that MRP2 is also expressed in some of 
them  such as ovarian carcinoma30, colorectal carcinoma31, leukemia32, and 
hepatocarcinoma33. Since the transfection of MRP2 cDNA to mammalian cells results in 
the conquest of drug resistance against antitumor drugs such as etoposide, vincristine, 
cisplatin, doxorubicin, Sorafenib and Erlotinib34, it is possible that the tumor cells 
overexpressing MRP2 gain the multidrug resistance. For example , in colorectal carcinoma, 
a significant correlation has been observed between MRP2 mRNA levels and cisplatin 
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resistance , Although it has been assumed that GSH is required for the excretion of P-gp 
substrate antitumor drugs , the precise mechanism for the transport still remains un clear35. 
 Depends on all these previous studies, we hypothesized that MRP2 expression level 
in HepG2-R to Erlotinib should be increase. 
 Aim of this study: Therefore, is convincible to suggestion a potential role for MRP2 
in drug resistance such as Erlotinib against HepG2 resistance cell line and Studying the 
role of multidrug resistance associated protein (MRPs) against sensitive HEPG2 cell line 
and resistant HEPG2R cell line. 
4.5  Material and Methods 
4.5.1  Detection of expression levels of MRP2 on sensitive and resistant HepG2 cell 
line  
  Western blot analysis of HepG2 protein lysate for resistant and sensitive cells line 
were prepared and done as previously described in western blot method page 63. Cells 
were lysed without any treatment with 1X RIPA buffer(Thermoscientific™Pierce™) 
containing protease and phosphatase inhibitors (Thermo Scientific™). The BCA protein 
assay was used to quantify total protein concentration. An amount of 20 µg was loaded 
onto 8% SDSPAGE per well, blotted onto 0.45micron nitrocellulose membrane for 120 
minutes at a current of 400mA. Because MRP2 is a large protein ,10% methanol was used 
in the transfer buffer instead of 20%. Subsequently, blocking was done with 5% BSA 
(Sigma Aldrich), and incubated with MRP2 primary antibodies overnight at 4°C. The 
membrane was subjected to the corresponding IR-conjugated secondary antibodies. The 
membrane was developed by using LiCOR odyssy imager. β-actin was used as a positive 
control. 
4.5.2  Study the proliferation effect of MK571 on HepG2-R alone and in combination 
with MMA 132 and MMA 102 
  The resistance HepG2-R cancer cells (A2780) were seeded in 96-well plate as 
5*104 cells/mL (100 µL/well). A serial dilution of MK571(Cayman Chemical (Ann Arbor, 
MI) was added after overnight incubation of the cells at 37°C and 5% CO2 at a final 
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concentration of 25 and 15µM, and DMSO (Acros Organics) was used as a control (0.1 
%). The cells were incubated with the MK571 for 48 hrs. After that 15 µL of 3-(4,5-
dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) (5 mg/mL PBS) 
(Hyclone™ L aboratories, Inc) were added to each well and the plate was incubated for 
another 4 hrs. The formazan crystals were solubilized by 100 µL acidified SDS solution 
(10% SDS/0.01 N HCl) (Fisher BioReagents). Absorbance was measured after 14 hrs of 
incubation at 37°C and 5% CO2 at 570 nm by Hidex Sense Microplate readers 
 The resistance HepG2-R cells were seeded as in cytotoxicity assay and incubated 
with MMMA132 and MMA102 for 24 hrs followed by addition of serial dilutions of 
MK571 (15 µL) then incubated for a total of 48 hrs. The viability of the cells was measured 
by MTT. The control was cells treated with DMSO36. 
 
4.6  Results 
4.6.1  Detection of expression levels of MRP2 on sensitive and resistant HepG2 cell 
line 
  The level of MRP2 was detected in HepG2 protein lysate for both resistant and 
sensitive cells line. Cells were lysed without any treatment. Western blot of resistance 
HepG2-R protein lysate demonstrated that MRP2 was highly expressed in HepG2-R about 
93% than sensitive cells. In contrast to the sensitive cells, the western blot of protein lysate 
for sensitive HepG2 showed lees level expression of MRP2 to be about 44% (Figure 4.3). 
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Figure 4.3 MRP2 expression level on resistant HepG2 and sensitive HepG2. 
 
4.6.2  Study the proliferation effect of MK571(MRP1, MRP2 inhibitor) on HepG2-R 
alone and in combination with MMA 132 and MMA102 
 To determine the proliferation effect of MK571 (MRP1, MRP2 inhibitor) alone and 
its effect on combination treatment with CIEA analogs (MMA132 and MMA102) on the 
resistant hepatocellular carcinoma cancer cells, the cells were treated for 48 hrs with 
MK571 at a final concentration of 25 and 15 µM, and viability was determined by MTT 
assay. Figure 4.4 and table 4.2 show the cytotoxic effects of the MK571 on resistant 
HepG2-R cell lines. The IC50 values of each MK571 were 18.5 µM on both concentration 
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of MK571 (25 µM and 15 µM). After that, the proliferation activity of each MMA132 and 
MMA102 combined with MK571 was tested by pre-incubating the cells with MMA132 
and MMA102, according to their respective IC50 values against HepG2-R (13 µM 
MMA132 and 20 µM MMA102), followed by incubation with serial dilutions of MK571. 
It was found that the most notably enhanced cell death was evident in cells treated with 
MMA132 (13 µM) combined with 15 µM of MK571 inhibitor, IC50 value was about 10 
µM, comparing to MMA132 alone and MK571 alone on HepG2-R. In this case the 
presence of MK571 led to enhance the effect of MMA132 on HepG2-R and reducing cell 
viability after 48 hrs. With MMA102, MK571 did not have any effect in these cells line 
HepG2-R.  
 From our data, MMA132 has antiproliferative activity on multidrug resistance 
against HepG2-R cell line alone more than the stander MRP2 inhibitor MK571. It’s 13 µM 
compared to MK571 (18.5 µM). Additionally, when it has been combined with MRP2 
inhibitor, the cytotoxicity increased to 10 µM. In general, all these results make our CIEA 
as a promising potential novel drug candidate that play a role for MRP2 in drug resistance 
such as Erlotinib in this study against HepG2 resistance cell line. 
Table 4.2 antiproliferation result against HepG2-R 
 
Compound IC50(µM) 
MK571 (25µM) 18.5 
MK571 (15µM) 19 
MMA132+MK571 10 
MMA102+MK571 18 
MMA132 13 
MMA102 20 
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Figure 4.4 Cells pretreated with 13 µM and 20 µM of MMA132 and MMA102, 
respectively, then treated with serial dilutions of MK571. The total incubation time was 48 
hrs. The cells treated with DMSO as a control. 
 
4.7 Discussion  
 Previous studies showed that MRP2 plays a role in drug resistance, just as MRP1 
does. Because MRP2 handles a wide range of conjugates similar to that of MRP1, it was 
believed to confer resistance to similar anticancer drugs as well20. Moreover, it has been 
suggested that MRP2 interfere in transporting several anticancer drugs15. In the present 
study, MRP2 expression level was different in comparison of sensitive cells to resistance 
cells.  
 MRP2 expression level was extremely low in sensitive HepG2 cell line and 
expressed two times less than resistance cell 44%. In contrast, the expression level of 
MRP2 was increased in resistant HepG2 cell line to Erlotinib 93% comparing to β-Actin 
as loading control. It has been reported before by Charls et al,2000, that MRP2 has been 
expressed in sensitive HepG2 cell line by western blot37.            
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  In addition, it was found an antisense  RNA  construct was introduced  into human 
hepatocellular carcinoma HepG2 cells,  resulting in enhanced sensitivity to several 
anticancer such as cisplatin2. 
These findings indicate that MK571 (MRP2 inhibitor) alone showed an inhibitory 
effect on resistant HepG2-R cancer cell lines 18.5 µM. Moreover, the combination of 13 
µM of MMA132 with 15 µM of MK571 leads to a significant increase in the inhibitory 
effect of MK571 from 18.5 µM to 10 µM. These combinations of drugs were less 
effectively with MMA102 (20 µM) and the data showed almost no change of MK571 
activity after this combination. 
MMA132 showed a potential inhibitory activity when it combined with MK571 
against HepG2-R as MRP2 inhibitor to enhance the activity of the stander inhibitor from 
18.5 µM to 10 µM after 48 hrs incubation.  
 The difference in structure and functional between MMA102 and MMA132 which 
makes MM132 more active biologically, that MMA132 and MMA102 are diastereomers 
with binding mode with the receptor. MMA132, which possess the stereochemistry of 
cucurbitacin D side chain, showed an outstanding binding mode with EGFR by forming 
H-bond with MET:769: A, which is same amino acids residues that erlotinib binds to in 
EGFR to induce anti-cancer activity by H bonding with the same amino acid MET:769-A. 
Also, MMA132 has hydrophobic interactions with the amino acids residues inside the 
binding pocket while MMA102 which has the opposite stereochemistry of cucurbitacin D 
demonstrated less binding affinity towards the EGFR binding site only with a hydrophobic 
interaction mode with the EGFR binding pocket. In general, this result proved the 
significant activity of MMA132 more than MMA102. 
 
4.8 Summary and Conclusion  
     In summary, MRP2 has been highly expressed in resistance HepG2 cell line to Erlotinib. 
In contrast the sensitive HepG2 cell line, the level of MRP2 was extremally low comparing 
to resistance cell line to Erlotinib. In addition, MK571 (MRP2 inhibitor) showed moderate 
activity against resistant HepG2 cell (18.5 µM). Also, combination 13 µM of MMA 132 
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with 15 µM of MK571 enhanced the activity of MK571 from 18.5 µM to 10 µM. On the 
other hand, combination of 20 µM of MMA102 with 15 µM does not change the activity 
of MK571. 
 In the meantime, cytotoxicity of MK571 enhanced significantly in combination 
with 13 µM of MMA132. A significant increase of MK571 cytotoxicity from 18.5 µM to 
10 µM. This clearly demonstrate the potential anticancer activity of MMA132 in 
controlling HepG2-R to Erlotinib.   
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